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Abstract
BISPHOSOHOGLYCERTAE MUTASE: A POTENTIAL TARGET FOR SICKLE
CELL DISEASE
By Anfal S. Aljahdali, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Medicinal Chemistry at Virginia Commonwealth University.

Virginia Commonwealth University, 2021.

Directors: Dr. Martin K. Safo
Professor, Department of Medicinal Chemistry
Dr. Yan Zhang
Professor, Department of Medicinal Chemistry

Bisphosphoglycerate mutase (BPGM) is a part of the erythrocyte glycolysis system.
Specifically, it is a central enzyme in the Rapoport-Leubering pathway, a side glycolytic pathway
involved in the regulation of the concentration of the natural allosteric effector of hemoglobin
(Hb), 2,3-bisphosphoglycerate (2,3-BPG). BPGM catalyses the synthesis and hydrolysis of 2,3BPG through its synthase and phosphatase activities. The synthase activity is the main role of
BPGM, while the phosphatase activity is low and is activated by the physiological effector, 2phosphoglycolate (2-PG) with the latter mechanism poorly understood.

xxiv

BPGM activity and 2,3-BPG levels in red blood cells (RBCs) have a significant role in
sickle cell disease (SCD) pathology. SCD patients experience a constant state of hypoxia that
results in increasing the level of 2,3-BPG as a compensatory mechanism to enhance oxygen
delivery to tissues. However, the abnormal increase in 2,3-BPG in RBCs of SCD patients
exacerbates the disease’s primary pathophysiology, which is the hypoxia-driven deoxygenatedsickle hemoglobin (HbS) polymerization, that in turn leads to RBCs sickling and consequent
numerous downstream multi-organ adverse effects.
Reducing the levels of 2,3-BPG by activating BPGM phosphatase activity using 2-PG has
been proposed as a potential therapeutic approach for SCD as 2-PG was found to have an antisickling property. Nonetheless, the actual activation mechanism of 2-PG on the phosphatase
activity or the binding mode of 2-PG to BPGM is not clear. Moreover, no drug screening studies
have been performed to identify small molecules against BPGM for therapeutic purposes.
The objectives of this project are to characterize the steady-state kinetics of BPGM
synthase and phosphatase activities, understand the mechanism of phosphatase activation, and
elucidate the atomic interaction of BPGM with 2-PG and other effectors such as citrate that can
provide valuable insight into their mechanism of actions and provide a framework for developing
small molecules with potential SCD therapeutic benefit. In addition, we aim to identify ligands
that modulate either BPGM phosphatase and/or synthase activity to reduce 2,3-BPG concentration
in RBCs.
First, the steady-state kinetics of BPGM synthase and phosphatase activities were
characterized using the previously reported coupled spectrophotometric synthase and phosphatase
activities assays. These assays were also optimized for drug screening experiments. Both assays

xxv

have limitations and proved challenging for drug screening. We also employed the colorimetric
malachite green assay to study BPGM phosphatase activity, as well as for compound screening.
Next, we elucidated the mechanism of phosphatase activity activation by 2-PG using
kinetic and X-ray crystallography studies. The kinetic study showed the mechanism of 2-PG
activation of BPGM to be mixed-type of noncompetitive and competitive, suggesting the binding
of 2-PG to the active site and to an allosteric or non-catalytic site of the enzyme. The crystal
structures of BPGM with 2-PG in the presence and absence of the substrate 2,3-BPG showed
binding of the 2-PG and/or 3-PGA (the reaction product of 2,3-BPG) at the expected active site,
and at a novel non-catalytic site at the dimer interface, in agreement with the kinetic analysis. The
structural studies of BPGM also showed conformational nonequivalence of the two monomeric
active sites: one site in a close catalytic conformation, and the second site in an open conformation,
with the residues at the entrance of the active site, including Arg100, Arg116, and Arg117, and the
C-terminus region disordered, which we propose to be induced by the dimer interface binding.
In order to gain further insight into the BPGM mechanism of action, we also co-crystallized
BPGM with citrate, a known BPGM phosphatase inhibitor. The co-crystal structure of BPGM with
citrate showed citrate binding to only one of the dimer active sites and to the dimer interface. The
kinetic and crystallographic findings suggest for the first time an allosterism or cooperativity
across monomers, in which the binding of a ligand at the dimer interface induces negative
cooperativity affecting the affinity of ligand binding at the second active site. In the BPGM•citrtate
binary complex, an extreme form of negative cooperativity, where half of the site reactivity is
observed, shows that only one active site appears to be functional.
Toward the objective of identifying small molecules modulators of BPGM activity for
therapeutic purposes, we identified several compounds that target the active site of BPGM using
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(1) in-house pharmacophore-based virtual screening and molecular docking; (2) machine learningbased molecular screening in collaboration with the pharmaceutical company Atomwise, and (3)
PGM1-004A, a known inhibitor of the homologous enzyme, phosphoglycerate mutase 1
(PGAM1). The compounds were tested for their effect on BPGM synthase and phosphatase
activities. Unfortunately, the compounds did not show any modulation except for PGMI-004A,
which shows a dose-dependent synthase inhibition with IC50 (50±11 µM). Several attempts were
made to co-crystallize BPGM with PGMI-004A but were unsuccessful. The novel allosteric site
at the dimer interface was also docked against a library of compounds, which identified several
potential binders. The top-scoring compounds will be obtained and tested in the near future.

CHAPTER 1

1. INTRODUCTION
1.1. Erythrocyte glycolysis

The major role of an erythrocytes or red blood cell (RBC) during its 120 days life span is
to transport oxygen (O2) from the lungs to the body tissues and deliver carbon dioxide from the
tissues back to the lungs as a waste product.1 RBCs need the energy to maintain their cellular
function. The main source of RBC’s energy is through anaerobic glycolysis since it lacks the
intracellular organelles such as nucleus and mitochondria.1,2
Glucose is consumed through the Embden-Meyerhof-Parnas (EMP) pathway and hexose
monophosphate shunt (HMP), which depend on the different O2 tensions between the lungs and
the tissues (Figure 1).1,3 In the lung, high O2 tension leads to a release of high O2 reactive species,
putting the RBCs in oxidative stress. Consequently, the glycolysis diverts into the HMP shunt at
the Glucose-6-phosphate step of the EMP pathway to generate nicotinamide adenine dinucleotide
phosphate (NADPH), which in turn generates a reduced form of glutathione (GSH) to protect
RBCs from oxidative stress (Figure 1). Also, during glycolysis, a reduced form of nicotinamide
adenine dinucleotide (NADH) is generated at the glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) step of the EMP pathway to help maintain RBCs in the reduced state, as the high O2
reactive species will oxidize the hemoglobin (Hb) bound iron from the ferrous state (Fe2+) to the
ferric state (Fe3+), forming methemoglobin. Methemoglobin lacks the ability to perform the normal
function of Hb, which is carrying O2 to the tissues. Thus, NADH functions to reduce Fe3+ back to
Fe2+ state, restoring the normal function of Hb.
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In contrast, in tissues where O2 tension is low, glucose is consumed mainly via the EMP
pathway, in which glucose is converted into lactate leading to the production of high energy
phosphate compounds, adenosine triphosphate (ATP), and NADH (Figure 1).4 In addition, the
glycolytic metabolite, 1,3-bisphosphoglycerate (1,3-BPG), bypasses the ATP producing step and
shunt into a side pathway called the Rapoport-Luebering pathway to synthesize 2,3bisphosphoglycerate (2,3-BPG), which is a potent allosteric effector of Hb that is responsible for
decreasing the affinity of Hb for O2, facilitating the unloading of O2 to tissues (Figure 1).
It should be noted that erythrocyte glycolysis is limited by the availability of the main
glycolytic enzymes in the cytosol. Under normal O2 tension, all the main glycolytic enzymes such
as GAPDH, aldolase, phosphofructokinase, pyruvate kinase, and lactate dehydrogenase form a
complex with the Band 3 membrane protein (cdB3) in the RBCs membrane, rendering the enzymes
inactive. However, in low O2 tension, deoxygenated Hb binds to cdB3, displacing the glycolytic
enzymes, and releasing them into the cytosol, thereby activating glycolysis.3

2

Figure 1. Erythrocyte glycolysis.
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1.2. The Rapoport-Luebering shunt

The Rapoport-Luebering shunt (also known as Bisphosphoglycerate shunt) is a side
biochemical pathway that was first described by Samuel Mitja Rapoport and his assistant Jane
Luebering in 1952.5,6 This side shunt is exclusive to mammalian RBCs and placenta and is
regulated by a single erythrocyte specific multifunctional enzyme, bisphosphoglycerate mutase
(BPGM).7 The reactions catalyzed in this pathway involve converting the glycolytic intermediate,
1,3-BPG, to its isomer 2,3-BPG, followed by conversion of 2,3-BPG to 3-phosphoglycerate (3PGA) in the EMP glycolytic pathway (Figures 1 and 2).7–9
At normal O2 saturation level, RBC glycolytic activity is balanced between ATP generation
to maintain cellular energy requirements and 2,3-BPG production for modulating the
oxygenation/deoxygenation status of Hb. However, in some instances, such as hypoxemia, low O2
tension activates glycolysis, which in turn increases the synthesis of 1,3-BPG, resulting in
increased production of 2,3-BPG in the erythrocyte. This adaptation mechanism influences the
efficiency of O2 dissociation from hemoglobin and optimizes O2 delivery to tissues.

4

Figure 2. Rapoport-Luebering shunt.

1.3. 2,3-Bisphosphoglycerate

2,3-BPG, also known as 2,3-diphosphoglycerate (2,3-DPG), is an organic phosphate
compound and was first identified by Greenwald in 1925 as a normal constituent in mammalian
erythrocytes.10 The physiological function of 2,3-BPG was determined 40 years later by the
Sutherland research group to be a cofactor for phosphoglycerate mutase 1 (PGAM1), a glycolytic
enzyme that catalyzes the interconversion of 3-PGA to 2-phosphoglycerate (2-PGA) in the cellular
glycolysis.11 Later, a second physiological function of 2,3-BPG was identified to be an allosteric
regulator of Hb to facilitate the release of bound O2 from Hb to tissues.12–14 2,3-BPG exists in the
RBCs with an equimolar concentration to Hb, approximately 5 mmol/L.15
Hb is a tetrameric allosteric protein, which undergoes different conformational changes
during the oxygenation and deoxygenation processes to allow binding and releasing of O2,
5

respectively. The two main conformational states of Hb are the T (tense) state, which possesses a
low O2 affinity (aka deoxygenated Hb), and the R (relaxed) state, which is a high affinity state (aka
oxygenated Hb). The R-state is an ensemble of several conformational states, including the R2,
R3, RR2, RR3, and the classical R.16,17
The allosteric effect of 2,3-BPG on Hb oxygen affinity is represented by the oxygen
dissociation curve (ODC) or the oxygen equilibrium curve (OEC) (Figure 3). This curve plots the
percent of O2 saturation of hemoglobin (sO2) against the O2 partial pressure in the blood (pO2).
The PO2 at 50% sO2 is expressed as P50 and measures the O2-affinity for Hb. The curve is sigmoidal
in shape due to the cooperative binding of O2 to Hb, meaning that the binding of one molecule of
O2 to one subunit of Hb tetramers facilitates the binding of O2 to the other subunits. The position
of the curve determines the affinity of O2 to oxygen. If the affinity of Hb to O2 is increased, the
OEC is shifted to the left, and the P50 value is decreased from the normal value of 26-27 mmHg
PO2 (Figure 3). If the affinity of hemoglobin to O2 decreased, the P50 value is increased, and the
OEC is shifted to the right. 2,3-BPG stabilizes the T-state conformation of Hb by binding to the
central water cavity between the two β-globin chains (Figure 3). Unlike oxygenated Hb, the β-cleft
is more accessible to 2,3-BPG in the deoxygenated Hb; thereby, 2,3-BPG preferentially binds to
deoxygenated Hb to stabilize the T-state. This causes a right shift of the OEC, decreasing Hb
affinity for O2 (i.e., increasing P50) and increasing the release of O2 to tissues.13,18–20 During the Tto-R transition, the pocket becomes smaller, and 2,3-BPG is expelled, allowing Hb to easily
transition to the high-O2 affinity R-state that easily binds oxygen.
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Figure 3. (A) The oxygen dissociation curve. (B) Binding of 2,3-BPG to deoxygenated Hb.
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1.4. Pathological role of 2,3-BPG in sickle cell disease

The production of 2,3-BPG is increased during hypoxia and/or low O2 tension conditions,
such as high altitude, respiratory distress, congestive heart disease, ischemia, and sickle cell
disease (SCD). The increase in 2,3-BPG level is a compensatory adaptation mechanism that
facilitates the release of O2 from Hb to tissues that need O2 the most. In SCD, 2,3-BPG is
abnormally high, presumably due to chronic hypoxia.21 The high 2,3-BPG concentration of RBCs
increases the proportion of the deoxygenated sickle Hb (HbS), which causes the primary
pathophysiology of SCD by inducing HbS polymerization and the concomitant RBCs sickling.22
On a molecular level, during the hypoxic condition, 2,3-BPG, in conjunction with
sphingosine-1-P (S1P), an intracellular hypoxia-responsive biolipid, binds to deoxygenated HbS,
forming a ternary complex that has been suggested to promote anchoring of deoxygenated HbS to
the RBCs membrane protein, cdB3, displacing the glycolytic enzymes (Figure 4).23–25 The release
of the main glycolytic enzyme GAPDH from cdB3 protein to the cytosol activates glycolysis
through the EMP pathway and suppresses the HMP shunt, resulting in enhancement of 2,3-BPG
production with a concomitant increase in oxidative stress, as well as increased concentration of
deoxygenated HbS,23,25 thereby, worsening HbS polymerization and RBCs sickling.
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Figure 4. Model of the involvement of 2,3-BPG in SCD pathogenesis.

1.5. Sickle cell disease
1.5.1.

Molecular and genetic bases of sickle cell disease

SCD is a hereditary hematological disorder caused by a single base-pair point mutation at
the sixth position of the Hb -globin gene, resulting in the expression of dysfunctional HbS. In
HbS, the hydrophilic glutamic acid residue at the surface of the β subunit (Glu6) is mutated to
the hydrophobic Valine residue (Val6).26,27 Under normal O2 saturation levels, both Hb and HbS
have an identical structure.28,29 However, during the hypoxic state, when HbS is deoxygenated,
the side-chain of the mutated Val6 of a Hb tetramer protrudes out to form intermolecular contacts
with the hydrophobic acceptor pocket (β2Ala70, β2Phe85, and β2Leu88) of an adjacent
9

deoxygenated HbS to form a polymer,26,28–31 leading to the formation of long, rigid, and insoluble
14 stranded fibers.26,30,32–36 The fiber integrity is further stabilized by secondary interactions with
adjacent HbS polymers, distorting the shape of RBCs from flexible biconcave disc cells into rigid
crescent sickle-shaped cells (Figure 5).26,27
1.5.2.

Pathophysiology and epidemiology of sickle cell disease

SCD has a complex pathophysiology that involves nearly all organ systems. Hypoxiainduced HbS polymerization is the hallmark of the disease and represents the primary
pathophysiological events that lead to subsequent secondary adverse effects (Figure 5).37 HbS
undergo multiple cycles of deoxygenation-induced polymerization and reoxygenation-induced
depolymerization resulting in the formation of irreversibly sickled RBCs, and subsequently the
initiation and propagation of downstream pathophysiological cascades, including deformability of
RBCs into crescent shape, dehydration of sickled RBCs,38 and damage of the sickled RBC’s
membranes.27,39 The damaged RBCs membranes release free Hb to the plasma leading to secretion
of pro-inflammatory and adhesive cytokines, activation of the coagulation system,40 and depletion
of nitric oxide level,41 which facilitate vaso-occlusion events. Recurrent vaso-occlusion episodes
can be manifested as serious complications, such as acute chest syndrome, leg ulcers, priapism,
painful crisis, and multi-organ damage or death (Figure 5).42,43
SCD is a global public health burden affecting over 100,000 people in the US, most of
whom are African-Americans and, to a lesser degree, Hispanic-Americans, and over 15 million
people worldwide.44 The number of affected people is expected to increase by 30% by 2050. 45
Individuals with SCD experience 20-30 years shorter life expectancy than people without SCD.43,44
In addition, SCD presents an economic burden with estimated annual lifetime costs of more than
$1 million per patient in the US alone (Figure 5).
10

Figure 5. Pathophysiology and epidemiology of SCD.
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1.5.3.

Current approved therapy of sickle cell disease

Currently, four drugs have been approved by the FDA for the management of SCD. These
include Hydroxyurea,48 L-glutamine,49 Crizanlizumab-tmca,50 and Voxelotor.51 The approved
drugs work by targeting multiple critical points in the pathophysiology of SCD.
1.5.3.1.

Hydroxyurea

Hydroxyurea (HU) is the first drug approved by the FDA for the treatment of SCD. It has
been the standard and ideal therapeutic agent since its approval in 1998.48 HU was originally
developed as an antineoplastic agent to treat myeloproliferative disorder. Later, it was found to
activate the production of fetal Hb (HbF), which does not polymerize, by inducing stress
erythropoiesis.52 HbF has a higher affinity to O2 compared to HbS. Therefore, increasing the
concentration of HbF will delay the HbS polymerization process and increase the solubility of
sickled RBCs.53 HU can also activate the synthesis of HbF through other mechanisms, such as
acting as a nitric oxide donor that results in an enhancement of cellular cyclic guanosine
monophosphate level and activation of protein kinase, which ultimately induces HbF
production.54,55 Additionally, HU was found to reduce inflammation, improves red cell rheology,
reduces adhesion and hemolysis of sickled RBCs.48,56 Despite its activity on multiple pathways, as
well as its clinical efficacy in both children and adults, HU exhibits a variation in SCD patients’
responses, and some patients have been reported to be refractory to HU therapy. 57 Also, the
reported poor compliance and the serious side effects such as myelosuppression tend to limit its
use.48
1.5.3.2.

L-Glutamine

The second approved therapy is L-glutamine (Endari), which is a precursor of GSH and
NAD. L-glutamine acts as an antioxidant, increasing the intracellular level of glutamine and
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enhancing the synthesis of NADH level to neutralize the oxidative stress in sickle RBCs.58,59 The
mechanism of action of L-glutamine only involves reduction of oxidative stress, and it has no
effect on HbS polymerization.58,60,61 In a multicenter, randomized, double-blind, phase III trial,
results demonstrated that oral L-glutamine supplementation twice daily at 0.3 g/kg dose for a total
of 48 weeks decrease the pain crises in adults and children over 5 years with SCD. 62,63 L-glutamine
was approved by the FDA in 2017 for acute complication of SCD in both adult and pediatric
patients older than 5 years.49,64 Nonetheless, the European regulatory body recommended against
approval of the medication due to limited evidence of efficacy in phase III trials.65,66
1.5.3.3.

Crizanlizumab-tmca (ADAKVEO)

Crizanlizumab-tmca is a humanized monoclonal antibody against the adhesion molecule
P-selectin. P-selectin lies on the surface of activated endothelium and platelets, and contributes to
the pathophysiology of SCD by initiating the vaso-occlusion process through promoting the
adhesion of leukocytes to the endothelium and platelets via P‐selectin glycoprotein ligand 1
(PSGL‐1).67,68 The anti-adhesive mechanism of crizanlizumab is through inhibiting the interaction
between P-selectin and PSGL-1, thereby increasing the blood flow and reducing vaso-occlusion.
Crizanlizumab has been shown to decrease the frequency of painful vaso-occlusive crises of SCD
patients in clinical trials from 2.98 per year (with placebo) to 1.63 per year in treated SCD patients,
a 45% overall decrease.69,70 It was approved by the FDA as an intravascular infusion to reduce the
frequency of vaso-occlusive events in adults and children with SCD.50 However, it is unclear if
this level of vaso-occlusive crises reduction (~1 per year) is sufficient to improve quality of life,
and the durability of long-term outcomes is uncertain. In addition, monoclonal antibodies are
expensive to produce and require monthly visits to an infusion clinic, which may limit patient
acceptance.
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1.5.3.4.

Voxelotor (GBT440)

Voxelotor (GBT440) is a Hb allosteric effector that inhibits the HbS polymerization by
forming a Schiff-base interaction with the αVal1 amine of HbS, stabilizing the non-polymer
forming R-state Hb, thereby increasing Hb O2 affinity with concomitant anti-sickling effect.51,71–
74

Voxelotor has been demonstrated to prolong RBCs half-life, delay HbS polymerization, and

inhibit RBCs sickling in sickle mice model and human.75,76 Voxelotor was approved by the FDA in
2019 for adults and pediatric patients of 12 years of age and older with sickle cell disease.51,75,77,78
Voxelotor is the only approved drug that directly acts to interfere with the HbS polymerization
process.72 FDA approval of Voxelotor for SCD was based on increased Hb levels and reduced
hemolysis in the HOPE trial and has yet to show significance on vaso-occlusion.

1.6. Approaches to target HbS polymerization for sickle cell disease therapy

The need for new and more effective therapy for SCD is high. Several research efforts have
been made or ongoing to explore different therapeutic approaches aimed to develop anti-HbS
polymerization agents. Among them are (1) HbF synthesis, (2) reduction of intracellular HbS
concentration, (3) blocking intermolecular contacts in the sickle polymer, (4) increase O2 affinity
of Hb, and (5) reduction of 2,3-BPG concentration.
1.6.1.

Fetal hemoglobin synthesis

HbF, a predominant form of Hb in fetal life, is a tetramer composed of two α-globin chains
and two γ-globin chains (α2γ2). HbF binds to O2 with greater affinity than normal adult Hb (HbA;
α2β2), facilitating O2 uptake by the fetus in the womb. After birth, γ-globin gene expression is
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silenced and gradually replaced by β globin to produce HbA.79 The beneficial role of elevated HbF
level in sickle cell disease patients was recognized in 1948 by pediatrician Janet Watson as she
observed the lack of SCD clinical complications in children in their first year. 80 Also, it was
observed that SCD patients, who carry a ‘hereditary persistence of fetal Hb’ gene, which is a
condition in which the RBCs have an increased amount of HbF than normal RBCs, have mild
symptoms, and they are less prone to sickle cell crises due to persistent γ-globin expression through
their adulthood.81 These observations, along with other biochemical studies that reported the
benefits of HbF in delaying the polymerization and improving the solubility of HbS, led to the
utilization of this approach as a therapeutic strategy for SCD treatment.53 HbF induction appears
to form hybrid heterotetramers with Hb S (α2βsγ) that lack the ability to incorporate into the HbS
polymer and thus reducing HbS polymerization.82 A number of agents have been reported to
induce HbF synthesis via their cytotoxic effect and epigenetic regulatory enzyme modification.
The cytotoxic agent, HU, is the typical HbF inducing agent and was the first drug approved for the
treatment of SCD.48 Epigenetic enzymes modulators have been investigated as an alternative
means to treatment with HU.83,84 The mechanism of action for HbF induction include reactivating
γ globin gene expression through inhibiting enzymes involved in HbF gene silencing. These
enzymes are DNA methyltransferase-1,85–87 histone deacetylase,88–95 and lysine demethylase-1.96–
101

A number of these enzymes’ inhibitors have shown to increase γ-globin expression in vitro, in

vivo and are under clinical trial for the treatment of SCD.102–105
1.6.2.

Reduction of intracellular HbS concentration

Studying the kinetics of hypoxia-induced HbS polymerization showed that HbS
experiences a delayed time until it polymerizes. This delayed time is strongly dependent on the
intracellular concentration of HbS. Therefore, a small reduction of HbS concentration can lead to
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potential improvement of HbS polymerization.38,106 One of the strategies to reduce the intracellular
concentration of HbS is by improving sickled RBCs hydration status through targeting the
membrane ion exchange channels, such as Gardose channels and/ or K-Cl cotransporter.107 The
activation of the membrane ion transporter in SCD increases the level of Ca 2+ in sickled RBCs
resulting in the activation of the Gardose pathway, which is Ca2+ activated K+ channel. The
activation will affect the permeability of the transport system resulting in the efflux of K+ and Clalong with loss of water.108–111 Gardose pathways can be inhibited through several compound, such
as clotrimazole, a known antifungal agent. Studies with clotrimazole showed improvement in
sickled RBCs hydration. Nevertheless, the clinical study was terminated because of dosedependent toxicity.111,112 Senicapoc, a novel Gardose channel blocker, improved sickled RBCs
hydration and reduced hemolysis.113,114 However, despite its efficacy, the clinical study was
terminated due to a lack of improvement in the frequency of vaso-occlusive crises in SCD
patients.115 Inhibition of KCl cotransporter has been achieved with a divalent cation, and increasing
intraerythrocytic Mg2+ content with Magnesium pidolate is under investigation as an SCD therapy,
either alone or in combination with HU.116,117
1.6.3.

Blocking intermolecular contacts in the sickle polymer

The polymerization of HbS is triggered by the single amino acid mutation on the surface
of β subunit (β6Glu → β6Val) via primary interactions between β6Val of one HbS molecule and
a hydrophobic pocket of a proximate HbS molecule. The polymer is further stabilized by several
secondary contacts.28,29,31,33,118 The molecular details of the fiber structure using X-ray
crystallography and light electron microscopy have led to the identification of the residues located
on the HbS surface that participate in the secondary polymer interactions. 34,119,120 It has been
observed that the Hb variant Stanleyville II (αAsn78 → αLsy78) increases HbS solubility and
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prevents HbS polymerization, resulting in a benign disease state.28,29,31,33,36,118 This observation
and others show that the abrogation of the secondary interpolymer contacts can lead to alleviation
of SCD symptoms. The disruption of the interpolymer secondary interactions by non-covalent
inhibitors has been studied as routes to develop potential therapeutic agents for SCD. These
inhibitors include alkyl urea,121–123 dichloromethane,124 aromatic amino acids, such as tryptophan,
phenylalanine, and phenylalanine and their derivatives.125–128 However, none of these compounds
showed promising results. The major drawback of this approach is that a high concentration of
drugs is required to bind non-covalently to HbS and/or also these compounds lack specificity.
Moreover, the interaction sites on the HbS surface are flat with no deep pockets in which
compounds can tightly bind.129
Also, efforts have been made to design peptide-based inhibitors targeting the primary
intermolecular polymer contacts, which include the N-terminal segments of the β-globin chain of
Hb (βPhe85/βLeu88 or/and β4Thr–β’73Asp). These peptide inhibitors have been shown to inhibit
HbS polymerization and improve the gelation of HbS. They overcame the challenges presented
with the flat surface of HbS as they can mimic the protein surface and interfere with the polymer
contacts.130–132 However, challenges remain, especially with respect to the high concentration of
compound required to reach the polymerization inhibitory potential.
Efforts are currently ongoing by several investigators to use covalent modifiers of Hb to
overcome the weak interactions of the non-covalent binders. Some of the compounds include
aromatic aldehydes, thiols, isothiocyanates, etc. 21,133
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1.6.4.

Increasing the oxygen affinity of Hb

Increasing the O2 affinity of HbS by covalent Hb allosteric effectors (AEH) has been shown
to be a viable strategy for inhibiting the hypoxia-induced HbS polymerization and preventing
RBCs sickling. Stabilization of the non-polymer forming R-state Hb by AEHs shifts the OEC to
the left, inducing an allosteric conformational change to produce Hb with high-affinity to O2 that
is resistant to polymerization. In contrast, stabilization of T-state by other class of AEHs shifts the
OEC to the right, producing low-affinity Hb that readily releases O2 to the tissues. Such
compounds obviously are not useful for treating SCD.
Different classes of AEH have been investigated and studied for their anti-sickling
properties, such as aromatic aldehydes, isothiocyanates, thiols, azolylacryloyl derivatives, and
ethacrynic acid derivatives.21,133,134 The most promising anti-sickling agents are the R-state
stabilizing aromatic aldehydes that bind to the α-cleft of the central water cavity of Hb and the Tstate destabilizing thiols that predominantly bind to the β-cleft on the surface of the Hb molecule
(Figure 6).

Figure 6. Hemoglobin-based anti-sickling agents. (A) Schematic representation of Hb tetramer
showing the binding sites of aromatic aldehydes, thiols, and 2,3-DPG. The α and β subunits are
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shown in cyan and gray, respectively. (B) Schiff-base interaction between aromatic aldehyde and
N-terminal αVal1 nitrogen at the α-cleft of Hb. (C) A disulfide bond between thiol and βCys93
sulfhydryl group at the β-subunit of Hb.
Aromatic aldehyde is the most studied class of the AEHs. The earliest studied aromatic
aldehydes are the natural product vanillin and the synthetic benzaldehydes molecules Valesresol135
and Tucaresol.136 These compounds have been reported to stabilize the R-state of HbS by
covalently binding to the N-terminal αVal1 nitrogen through Schiff base formation (Figure
6).21,137,138 The less than desirable pharmacokinetics and/or pharmacodynamics properties of
Vanillin and Valeresol led to the termination of their preclinical and clinical phase 1 studies,
respectively. On the other hand, Tucaresol exhibited an improved pharmacodynamics properties,
yet a phase II clinic trial was terminated due to immune system-related side effects.136,139 The
results of Vanillin, Valeresol, and Tucaresol encouraged the subsequent structural based drug
discovery studies that led to the discovery of 5-hydroxymethyl-2-furfural (5-HMF) as a potential
anti-sickling agent.137,140 5-HMF showed significant anti-sickling properties in vitro and in vivo,
yet the phase II clinical study was terminated due in part to limited bioavailability as a result of
metabolic oxidation of the aldehyde moiety.141 Using the vanillin pharmacophore, several pyridyl
derivatives of e.g. INN-312, INN-298, etc.,138,142 were synthesized and studied. These compounds
were shown to exhibit dual anti-sickling properties by possessing a stereospecific inhibition of the
polymer interaction via binding to the Hb αF-helix surface, in addition to their primary hypoxiainduced anti-sickling effect. The αF-helix is known to stabilize the polymer through secondary
interactions between adjacent deoxygenated HbS molecules.138 Furthermore, several novel antisickling agents such as TD, VZHE, and PP derivatives have been synthesized and shown to have
superior anti-polymerization properties than the previous aromatic aldehydes.143–146
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Structural modification of INN-312 by a Global Blood Therapeutics scientist resulted in
the discovery of the FDA approved medication, Voxelotor, that showed superior anti-sickling
properties compared to all other aromatic aldehydes. Unlike the previous aromatic aldehydes that
bind to Hb in a 2:1 ratio, Voxelotor binds to HbS tetramer in 1:1 stoichiometry reducing the dosing
requirement to achieve the therapeutic effect. Nevertheless, unlike VZHE and PP compounds that
are able to prevent sickling under complete anoxia (O2-independent anti-sickling effect), in
addition to their primary O2-dependent anti-sickling activities, Voxelotor only shows an O2dependent anti-sickling effect. Thus, while VZHE-039 and the PP compounds will be able to
achieve disease-modifying benefits at low O2 environments or areas of local hypoxia that are
commonly seen in microvascular occlusion in SCD, Voxelotor cannot, making these compounds
superior.
Triazole Sulfide is the second class of the promising AEH, forming a disulfide bond to
βCys93 on the surface of Hb (Figure 6).147 This interaction leads to destabilization of the T state
Hb by preventing the formation of the T-state salt bridge interaction between βAsp94 and βHis146,
thereby left-shifting the HbS allosteric equilibrium to the non-polymerizing high O2-affinity
HbS.148,149 TD-1, is the example of this class, and was demonstrated to increase HbS oxygenation
and reduce RBC sickling.147
1.6.5.

Reduction of 2,3-BPG concentration

2,3-BPG is a glycolytic intermediate found in high concentration in the erythrocytes. The
main function of 2,3-BPG is to lower the O2 affinity of Hb by binding with high affinity to
deoxygenated Hb, allowing O2 release to tissues. In SCD, the concentration of 2,3-BPG is
abnormally elevated as a response to hypoxia. The high 2,3-BPG concentration contributes to the
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SCD pathology by exacerbating HbS polymerization and RBCs sickling.22,150 For this reason,
reducing the concentration of 2,3-BPG has been proposed as a strategy to treat SCD.
There are two proposed approaches to decrease 2,3-BPG levels in erythrocytes. One is by
targeting BPGM enzyme, which is the enzyme responsible for the synthesis and hydrolysis of 2,3BPG in erythrocyte. The second approach is by targeting the erythrocyte pyruvate kinase-R (PKR),
which is the rate-limiting enzyme in glycolysis that catalyzes the interconversion of
phosphoenolpyruvate to pyruvate and ATP in the last step of the glycolytic pathway (Figure 1).
Recent efforts by FORMA therapeutics have identified a novel allosteric activator for PKR
named (FT-4202). The activation of PKR activity resulted in lowering the upstream 2,3-BPG level,
increasing Hb’s O2 binding capacity in sickled RBCs, and decreasing vaso-occlusive crises.154
Currently, FT-4202 is undergoing phase 1 clinical trials to evaluate the safety, pharmacokinetics,
and pharmacodynamics profile in SCD patients (NCT03815695).151
Direct targeting of BPGM with compounds is yet to be fully investigated. An earlier study
showed that activation of BPGM phosphatase activity by divalent anion metabisulfite and the
physiological activator, 2-phosphoglycolate (2-PG), lead to a decrease in the 2,3-BPG level.152–154
Additionally, another study showed that in vitro manipulation of the phosphatase activity by
incubating RBCs with exogenous glycolate resulted in decrease of the 2,3-BPG level that
consequently improved the solubility and sickling tendency of sickled RBCs.150,155 This study also
concluded that decreasing 2,3-BPG level by modulating BPGM activity inhibits HbS
polymerization through three different mechanisms: (1) direct inhibition by elevation of the
equilibrium solubility; (2) indirect inhibition by increasing O2 affinity and stabilizing the
oxygenated R-state Hb conformation; (3) decrease intracellular Hb concentration.150,155 Also, a
recent study has evaluated the effect of 2,3-BPG elimination on SCD pathology by a complete
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knockout of the BPGM gene in Townes model mice. The results showed that complete knockout
of BPGM showed increased Hb O2 affinity and improve RBCs sickling.156
From the foregoing, it is clear that 2,3-BPG concentration in RBCs can be directly
modulated through targeting the BPGM phosphatase/synthase activities. Thus, reducing the 2,3BPG level is a potential approach to inhibit HbS polymerization and reduce RBCs sickling (Figure
7). This approach will be further investigated in this project.

Figure 7. Effect of BPGM modulation in sickle cell disease.

1.7. Bisphosphoglycerate mutase: target for sickle cell disease drug discovery

Bisphosphoglycerate mutase (BPGM) is a member of the phosphoglycerate mutase
(PGAM) enzymes family, which is a group of glycolytic enzymes essential for cell glycolysis and
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regulation of 2,3-BPG. In mammals, there are two types of phosphoglycerate mutases: 2,3-BPGdependent PGAM, also known as phosphoglycerate mutase 1 (PGAM1), and BPGM. These
enzymes are closely related to each other, share a 50% sequence identity, and catalyze the same
three intermolecular phosphoryl transfer reactions (synthase, phosphatase, and mutase) with a
relatively different catalytic rates and substrate specificities.157 Unlike PGAM1, which is expressed
in nearly all tissues, BPGM is specifically expressed in erythrocytes and placenta158 making it
crucial for the regulation of 2,3-BPG in erythrocytes.5,159
1.7.1.

Structure of Bisphosphoglycerate mutase

BPGM is a homodimer with a molecular weight of 60 kDa.160 Each monomer of BPGM
has two domains, which consist of 10 α helices (named α1- α10) and 6 β sheets (named βA-βF).
The BPGM catalytic core is made up of five parallel (βA, βB, βC, βD, and βF) and one anti-parallel
(βE) β sheets flanked by six α helices.160 The active site of BPGM on each monomer is a hollow
shape and defined by His11, His188, Arg10, and Arg62 that reside at the bottom of the pocket.
The mouth of the active cleft is composed of Lys18, Asn20, Arg100, Arg116, and Arg117 on one
side and Ile208, Asn209, and Thr211 on the other side. The active site has a positive electrostatic
potential due to the presence of several basic residues, such as Arg10, Arg62, Arg90, Arg100,
Arg116, and Arg117, to accommodate the negatively charged substrates (1,3-BPG, 2,3-BPG, and
3-PGA).160,161 The C-terminus of BPGM lies on the rim of the entrance of the active site pocket
with the side-chain of Gln251 incorporated inside the active site pocket, accommodating the
binding of substrate, as well as facilitating the phosphorylation process and stabilizing the
phosphoenzyme form. Therefore, the C-terminus plays an important role in the functional
properties of the enzyme.160 Deletion of the last 7 residues of the C-terminal tail residues has been
shown to abolish the three catalytic activities of the protein.159
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The two monomers of BPGM are related by two-fold non-crystallographic symmetry. The
dimer interface is formed by the interaction between the surface of βC-sheet and an α2-helix of
each monomer.160 The dimer interface is stabilized with hydrogen-bond interactions between
residues that are conserved in BPGM enzymes, including Glu51, Phe52, Asp53, His65, Glu77,
and Arg140. The side-chains of Ile64, Trp68, Leu69, Leu71, and Val81 from each monomer form
the hydrophobic dimerization core of the enzyme.160
1.7.2.

Function of Bisphosphoglycerate mutase

The BPGM enzyme was first studied by Rapoport and Luebering from rabbit erythrocyte. 5,6
At first, it was believed that the three catalytic reactions of BPGM were regulated by multiple
different enzymes due to the irreversible nature of the synthase and the phosphatase reactions.162,163
Later, it was concluded that the three catalytic activities are catalyzed by a single multifunctional
enzyme and at the same active site.9,164,165 The regulatory mechanism of BPGM and its catalytic
properties have been extensively studied from human RBCs by the Rosa, Rose, and Sasaki
research groups.9,154,166–169 Rosa et al. further studied the properties and the kinetics of BPGM by
developing a recombinant human BPGM expressed in Escherichia coli (E.coli).159,170–172
BPGM regulates the intraerythrocytic level of 2,3-BPG by catalyzing the two irreversible
reactions that are responsible for the synthesis (synthase) and degradation (phosphatase) of 2,3BPG. 2,3-BPG synthase activity (Figure 8: Reaction 1) is the main reaction of the enzyme, and it
is inhibited by its own product, 2,3-BPG, with a Ki of 0.85 µM. However, the consequent binding
of 2,3-BPG to deoxygenated Hb protects the BPGM from the product feedback inhibition.162,173
The phosphatase activity (Figure 8: Reaction 2), which is responsible for the hydrolysis of 2,3BPG to the glycolytic intermediate 3-PGA, is lower than the synthase activity and is stimulated by
several effectors, including chloride, sulfite, inorganic phosphate, and most potently, 2-PG, a
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physiological activator that exists in RBCs with 2-5 µM concentration.154 Also, the BPGM enzyme
has been shown to exhibit, to a lesser extent, a mutase activity (Figure 8: Reaction 3), which is
responsible for the interconversion of 3-PGA to 2-PGA.154,159 However, the mutase activity of the
enzyme has been reported to be physiologically insignificant.162

1,3-BPG + 3-PGA

2,3-BPG + 3-PGA

2,3-BPG + H2O

3-PGA + Pi

(Reaction 2)

3-PGA + 2,3-BPG

2-PG + 2,3-BPG

(Reaction 3)

(Reaction 1)

Figure 8. The Three enzymatic reactions of BPGM; synthase activity (Reaction 1), phosphatase
activity (Reaction 2), mutase activity (Reaction 3).

1.7.3.

Proposed mechanisms of action

The mechanism of action of the three catalytic activities of BPGM was reported to operate
via a double displacement (ping pong) mechanism that involves the formation of Hisphosphorylated enzyme as an intermediate in the catalytic reaction. 7,159,172,174 In such a mechanism,
the first step requires the binding of the substrate 1,3-BPG or 2,3-BPG to the free enzyme. The
second step involves the phosphorylation process of the active site residue His11, converting the
enzyme into an active phosphoenzyme intermediate and 3-PGA as a first product. The last step is
the transfer of phosphate group from the His11 residue to the 3-PGA, synthesizing 2,3-BPG in the
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case of the synthase reaction or transfer of phosphate group from the His11 residue to a water
molecule, hydrolyzing the phosphoenzyme in the case of the phosphatase reaction.172
The three catalytic reactions of BPGM have been reported to occur at the same active site
with two distinct binding sites for the substrates, one for bisphosphoglycerate (1,3-BPG and 2,3BPG) and another for monophosphoglycerate (3-PGA and 2-PG).174 However, based on the crystal
structure of BPGM in complex with 2,3-BPG (PDB ID 2H4Z), as well as BPGM in complex with
3-PGA (PDB ID 2H4X), the two substrates have appeared to have similar binding mode and
interactions at the active site.161
1.7.3.1.

BPGM synthase reaction

The synthase reaction is the primary activity of BPGM. The stoichiometry of the synthase
activity of BPGM has been reported as follows 166

2,3-BPG + 3-PGA

1,3-BPG + 3-PGA

The synthase reaction starts with the binding of 1,3-BPG to the free BPGM in the first step.
3-PGA + Pi
2,3-BPG + H2O
The second step is the transfer of the 1-phosphate group of 1,3-BPG to the active site residue His11
forming a phosphorylated His11 and the hydrolysis product, 3-PGA. There is a discrepancy in the
2-PG + 2,3-BPG
3-PGA + 2,3-BPG
literature regarding whether the 3-PGA dissociates from the active site to allow the binding of a
second 3-PGA molecule to complete the synthesis reaction or if 3-PGA stays in the active site as
an intermediate and undergo re-phosphorylation to be converted to 2,3-BPG.
Early reports by Rose et al. postulated that the release of 3-PGA from the active site after
the dephosphorylation of 1,3-BPG, followed by the binding of another molecule of 3-PGA as a
second substrate/cofactor.7,175 Then, the phosphoryl group transfers from His11 to 2-hydroxyl
group of 3-PGA, synthesizing 2,3-BPG. In addition, Rose reported that the rate-limiting step for
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the synthase reaction is the phosphorylation of His11.8 However, a recent study by Chu et al. 176
using a combination of classic molecular dynamic (MD) and quantum mechanics/molecular
mechanics (QM/MM) metadynamics and the umbrella sampling method reported that the ratelimiting step of the synthase reaction is the re-phosphorylation of 3-PGA into 2,3-BPG. According
to Chu, the synthase reaction includes three steps catalyzing the conversion of 1,3-BPG to 2,3BPG with the formation of 3-PGA as an intermediate (Figure 9). The first step involves the fast
phosphorylation of His11 by the acyl phosphate group of 1,3-BPG. Then, the hydroxyl group of
3-PGA rotates toward the glutamic acid residue (Glu89) to allow for proton transfer from the
hydroxyl group of 3-PGA to the carboxylic group of Glu89 (Figure 9). Next, the electrostatic
repulsion between the negatively charged phosphoryl oxygen atom of His11 and the negatively
charged carboxyl group of 3-PGA helps to position the 2-hydroxyl group of 3-PGA for rephosphorylation to form 2,3-BPG. 178

Figure 9. Mechanism of action of the BPGM synthase activity.
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1.7.3.2.

BPGM phosphatase reaction

The phosphatase reaction of the enzyme involves the hydrolysis of 2,3-BPG into 3-PGA
and inorganic phosphate (Figure 8: Reaction 2). The hydrolysis product, 3-PGA, has been
demonstrated to dissociate from the active site after the enzyme phosphorylation. Then, the
activated water molecule at the active site acts as a second substrate hydrolyzing the
phosphoenzyme.154 The high-resolution crystal structures of BPGM in complex with 2,3-BPG
shed light on the actual catalytic mechanism of the phosphatase activity.161 The co-crystal
structures revealed snapshots of the histidine phosphorylation process that follows SN2 reaction,
which entails the imidazolium ring of His11 acting as a nucleophile to attack and remove the 2phosphate group of 2,3-BPG to form a phosphoenzyme intermediate.161 The MD/QM/MM study
of the phosphatase reaction performed by Chu et al. provides support to the described
crystallographic study of BPGM in complex with 2,3-BPG (Figure 10).176 According to Chu,
His11 first attacks the 2-phosphate group of 2,3-BPG. As a result, the oxygen atom of 3-PGA will
carry a negative charge that attracts the proton transfer from Glu89 to 3-PGA to be liberated.14,27
Following, the negatively charged Glu89 activates a water molecule in the catalytic site to accept
the phosphate group from the phosphorylated His11, thereby hydrolyzing the phosphoenzyme. In
the case of stimulated phosphatase activity by the activator 2-PG, the exact mechanism of
activation is not conclusive, but it has been proposed that 2-PG binds to the active site as a second
substrate, facilitating the dephosphorylation of phosphoenzyme to the water molecule.154,166
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Figure 10. Mechanism of action of BPGM phosphatase activity.

1.7.3.3.

BPGM mutase reaction

The mutase reaction is responsible for the interconversion of 3-PGA to 2-PGA in
the main glycolysis pathway (Figure 8: Reaction 3). The steady-state kinetics of the mutase
reaction of BPGM have not been studied in detail, like the synthase and phosphatase reactions. It
is assumed that the mutase reaction operates by the same mechanism as that of the homologous
PGAM1, which is the enzyme that mainly catalyzes this reaction.162
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CHAPTER 2

2. RATIONALE, GOAL, HYPOTHESIS, AND SPECIFIC AIMS
2.1. Rationale

Sickle Cell Disease (SCD) has been known for over 100 years, yet the development of safe
and effective treatment of the disease still poses significant challenges. For example, although
Hydroxyurea (HU) is the most proven therapeutic approach for SCD as evidenced by the sustained
clinical use for over two decades, a reported lack of response to HU in up to 30% of patients and
poor compliance, tends to limit its use.48 Though L-glutamine (Endari) is approved by the FDA to
treat SCD in the US, the European Union has recommended against approval due to limited
evidence of efficacy in phase III trials.65,66 The recently FDA approved medication for SCD,
Voxelotor, is based on increased hemoglobin (Hb) levels and reduced hemolysis in patients without
improving pain or vaso-occlusion.177 These surrogate end-points are thus not long-term clinical
outcomes. Therefore, the limited availability of SCD treatment calls for an urgent need for new
targeted therapies.
SCD has complex pathophysiology with a single root cause, the polymerization of
deoxygenated sickle Hb (HbS), which is exacerbated by 2,3-bisphosphoglycerate (2,3-BPG)
elevation in red blood cells (RBCs) as a result of glycolysis activation in response to
hypoxia.22,150,178 Therefore, a logical approach to treat SCD is to target bisphosphoglycerate
(BPGM) enzyme, an enzyme responsible for the regulation of the 2,3-BPG concentration in the
erythrocyte.
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BPGM is a multifunctional enzyme in the Rapoport-Leubering pathway that regulates the
intraerythrocytic level of 2,3-BPG by catalyzing two irreversible reactions responsible for the
synthesis (synthase) and degradation (phosphatase) of 2,3-BPG that occur at the same active site.9
The pharmacological inhibition of the 2,3-BPG synthase activity, or activation of 2,3-BPG
phosphatase activity, or both, may be an intriguing approach to decrease 2,3-BPG level in
erythrocyte. However, despite the long-standing knowledge about the involvement of 2,3-BPG in
SCD pathophysiology, this approach has not been well studied for the treatment of SCD due, in
part, to a lack of understanding of the BPGM catalytic mechanisms. Therefore, one objective of
this study is to understand the kinetics of BPGM synthase and phosphatase activities.
The synthase activity of BPGM is the main activity of the enzyme. The phosphatase
activity of BPGM is low (approximately 1,000-fold lower than the synthase activity), but it is
physiologically activated by the endogenous substance, 2-phosphoglycolate (2-PG).150 The
mechanism involved in the phosphatase activation by 2-PG is a long-standing puzzle that is yet to
be explored. Thus, the second objective of this study is to understand the mechanism of
phosphatase activation, as well as the atomic interaction of BPGM with 2-PG, which is expected
to provide valuable insight and foundation for design of small molecule phosphatase activators or
synthase inhibitors with potential therapeutic benefit.
Activation of BPGM phosphatase activity has been studied by incubating sickle RBCs with
exogenous glycolate, which resulted in a reduction of 2,3-BPG levels and inhibition of RBC
sickling.150 These observations suggest that the synthase/phosphatase activity of BPGM could be
potential targets for achieving anti-sickling effect. Therefore, the third objective of this project is
to identify and screen for active site modulators of BPGM for potential treatment of SCD.
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Reported biochemical assays for the synthase and phosphatase activities, such as
radioactive and spectrophotometric coupled activity assays possess challenges, especially for highthroughput screening purposes.154,166,170,171,175,179 As such, the fourth objective of this project is to
develop a direct, fast, and convenient assay suitable for compounds screening.
In conclusion, the ultimate research goal is to identify BPGM modulators that reduce the
concentration of 2,3-BPG in RBCs to prevent pathological hypoxia-induced HbS polymerization
and RBC sickling for the treatment of sickle cell disease.

2.2. Hypothesis

Inhibitors of synthase and/or activators of phosphatase activities of BPGM may decrease
the level of 2,3-BPG and prevent hypoxia-induced HbS polymerization and RBCs sickling.

2.3. Specific Aims

Specific Aim 1: Elucidate the kinetics of the synthase and phosphatase activities of BPGM
and optimize the activity assays for compounds screening.
Specific Aim 1A: Kinetic characterization of BPGM synthase activity and
optimization of the BPGM.GAPDH synthase coupled assay.
Specific Aim 1B: Kinetic characterization of BPGM phosphatase activity and
optimization of the malachite green assay and GAPDH.PGK.BPGM coupled assay.
Specific Aim 1C: Understanding 2-PG activation mechanism of BPGM
phosphatase activity using GAPDH.PGK.BPGM coupled assay.
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Specific Aim 2: Elucidate the atomic interaction of BPGM phosphatase with its effectors,
and identify allosteric binding site(s) of BPGM.
Specific Aim 2A: X-ray crystallography studies of BPGM in complex with 2-PG
or citrate.
Specific Aim 2B: The use of the computational solvent mapping tool (FTMap) to
identify allosteric binding sites of BPGM.
Specific Aim 3: Identification of BPGM synthase inhibitor and/or phosphatase activators
that can be used as leads for SCD drug discovery.
Specific Aim 3A: Identification of BPGM modulators targeting BPGM active site.
Specific Aim 3B: Identification of BPGM modulators targeting BPGM dimer
interface.
Specific Aim 3C: Investigation of modulators effect on BPGM phosphatase and
synthase activity.
Specific Aim 3D: Elucidate the X-ray crystallographic binding between BPGM and
PGMI-004A.
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CHAPTER 3

3.

SPECIFIC AIM 1: Elucidate the kinetics of the synthase and phosphatase activities
of BPGM and optimize the activity assays for compounds screening

Bisphosphoglycerate mutase (BPGM) enzyme plays a major role in regulating hemoglobin
(Hb) oxygen affinity by controlling the concentration of 2,3-bisphosphoglycerate (2,3-BPG) level
in human red blood cells (RBCs) through its synthase and phosphatase activities in a pathway
called the Rapoport-Leubering pathway.6,7,13 As previously noted, 2,3-BPG is the major allosteric
modulator for Hb, binding preferentially to deoxygenated Hb to shift the protein’s allosteric
equilibrium from high-oxygen-affinity relaxed (R) state to the low-oxygen-affinity Tense (T) state,
facilitating tissues oxygenation.12,18
BPGM is the central enzyme of the Rapoport-Leubering pathway, mainly catalyzing the
irreversible synthesis of 2,3-BPG from the glycolytic intermediate 1,3-bisphosphoglycerate (1,3BPG) (Figure 8; Reaction 1), referred to as synthase activity. Interestingly, BPGM also regulates
the concentration of 2,3-BPG in the cell through a phosphatase activity by catalyzing the
hydrolysis of 2,3-BPG to the glycolytic metabolite, 3-phosphoglycerate (3-PGA), and inorganic
phosphate (Pi) (Figure 8; Reaction 2).7,8,154,170,179 This phosphatase activity is activated by a
physiological activator, 2-phosphoglycolate (2-PG).154 In addition, BPGM has a minor mutase
activity that catalyzes the reversible interconversion of 3-PGA to 2-phosphoglycerate (2-PGA)
(Figure 8; Reaction 3) in the main glycolytic pathway, a reaction mainly catalyzed by the
homologous enzyme phosphoglycerate mutase 1 (PGAM1).9 One objective is to gain further
insight into the mechanisms of both the phosphatase and synthase activities that are not yet fully
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understood. Another objective of this study is to elucidate 2-PG activation mechanism and binding
mode to BPGM.
Due to BPGM is central and important role in physiological regulation of 2,3-BPG, it is
recognized that modulation of BPGM activity to decrease 2,3-BPG concentration would have an
important clinical implication for sickle cell disease (SCD).150,180,181 People with SCD have
unusually high levels of 2,3-BPG, which is implicated in the disease pathophysiology by
promoting hypoxia-induced HbS polymerization and RBC sickling.22,150 Another objective of this
project is to identify lead compounds to inhibit the synthase activity and/or activate the
phosphatase activity of BPGM to reduce 2,3-BPG concentration, which potentially could be
developed for SCD therapy. Achieving this goal requires availability of direct and simple assays
for drug screening.
The BPGM synthase and phosphatase activities have been studied using two main
methods: a continuous coupled enzymatic activity assay and a radiolabeled activity
assay.152,154,166,167,170,179 In order to find a suitable assay for screening of potential BPGM
modulators, the activity and kinetic characterizations of the synthase and the phosphatase activities
of BPGM were studied using previously reported coupled assays.152,154,166,167,170,179 Furthermore,
in an alternative to the radiolabeled activity assay, a direct non-radioactive colorimetric assay,
malachite green assay, was also utilized for measuring BPGM phosphatase activity.

3.1. Specific Aim 1A: Kinetic characterization of BPGM synthase activity and
optimization of the BPGM.GAPDH synthase coupled assay.

The synthase activity of BPGM was tested in a continuous, spectrophotometric, enzymecoupled assay in which the production of 2,3-BPG is coupled with the activity of glyceraldehyde35

3-phosphate dehydrogenase (GAPDH), catalyzing the reduction of nicotinamide adenine
dinucleotide (NAD) to the reduced form (NADH), that can be detected spectrophotometrically at
A340 nm. The overall reactions of the assay are as follow:

GAPDH
1,3-BPG + NADH

GAP +NAD+ + Pi
BPGM
1,3-BPG + 3-PGA

(Reaction 1)

2,3-BPG + 3-PGA (Reaction 2)

Since the substrate of BPGM synthase, 1,3-BPG, is commercially unavailable due to its
instability and propensity to rapidly isomerize to 2,3-BPG, the first step of this assay is to
enzymatically synthesize 1,3-BPG. 1,3-BPG was synthesized from glyceraldehyde-3-phosphate
(GAP) by GAPDH (Reaction 1). GAPDH catalyzes the synthesis of 1,3-BPG by reducing NAD
to NADH and this conversion is monitored spectrophotometrically by the increase in the
absorbance signal at A340 nm. The reaction course is followed until it reaches a plateau, which
indicates a steady-state formation of 1,3-BPG. Following, an aliquot of BPGM is added to the
reaction mixture and further increase of the absorbance signal is observed (Reaction 2). The
formation of NADH following the addition of BPGM corresponds to 2,3-BPG production and
BPGM synthase activity. In this assay, the auxiliary enzyme GAPDH (2 U/mL), GAPDH
substrates, GAP (3 mM), and NAD (1 mM) were in high concentrations to ensure that the
saturation condition of the assay mixture is achieved for the BPGM to be the only limiting factor
for the assay. The reported Km values of GAP and NAD for GAPDH are 77 µM and 57 µM,
respectively; thus, the concentrations of the substrates used in the assay were in high excess.182
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In the first step of the assay reaction (Reaction 1), only 0.1% of the initial concentration
of GAP (3 mM) was utilized to synthesize 1,3-BPG. Then, the addition of BPGM to the assay
mixture consumed the initially formed 1,3-BPG to synthesize 2,3-BPG (Figure 11). Thereafter,
the consumption of 1,3-BPG forces the remaining GAP and GAPDH in the reaction mixture to
proceed in the forward direction reaction producing more 1,3-BPG that is directly related to 2,3BPG synthesis (Figure 11).

Figure 11. (A) BPGM synthase coupled assay reactions. (B) BPGM synthase progress curve; blue
line corresponds to 1,3-BPG production and black line corresponds to 2,3-BPG production.

The assay was performed in a 1 mL final assay volume in a quartz cuvette using Agilent
8453 UV-VIS spectrophotometer. A time-dependent reaction was assessed to select the linear
region of the enzymatic reaction to study the enzymatic activity. From the reaction progress curve,
the assay duration was set to 300 s (Figure 11).
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BPGM activity was measured by varying the concentration of BPGM (0.1 -2.5 µM) and
the result showed a linear dependence of the activity to the enzyme concentrations (Figure 12).
BPGM activity was measured by calculating the slope of the tangent line in the reaction progress
curve (Figure 11 B). A concentration of 0.3 µM was selected as a standard concentration to be
used in studying the enzyme activity and subsequent compounds screening assay. The assay was
validated by determining the effect of 2-PG on the synthase activity. 2-PG has been reported as an
inactivator of the synthase activity.166
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Figure 12. Dependence of the synthase reaction velocity on the enzyme concentrations.

The activity of the enzyme was determined to be 0.07 µmole of NADH/min and in the
presence of 1 mM of 2-PG, the activity was reduced by half to 0.03 µmole of NADH/min (Table
1).
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Table 1. BPGM synthase activity and specific activity in presence and absence of 2-PG.
Enzyme activity

Specific activity

µmole of NADH/min

µmole of NADH/min/mg

Control

0.07 ± 0.01

8 ± 0.5

With 1mM 2-PG

0.03 ± 0.02

3.3 ± 0.8

The Michaelis-Menten constant of 1,3-BPG for BPGM could not be obtained due to the
high instability of 1,3-BPG.172 Since 1,3-BPG has to be enzymatically synthesized at the time of
the assay, and it was difficult to vary the concentration of 1,3-BPG to measure the Km value.
Regardless of this limitation, the synthase coupled activity assay will be used for screening BPGM
modulators. However, due to its cumbersome nature, it cannot be used for high-throughput
screening, but rather as a hit confirmatory assay.

3.2. Specific Aim 1B: Kinetic characterization of BPGM phosphatase activity and
optimization of the malachite green assay and GAPDH.PGK.BPGM coupled
assay
3.2.1.

Kinetic characterization of BPGM phosphatase activity and

optimization of the malachite green assay
BPGM phosphatase activity was studied using a commercially available malachite green
assay kit, a colorimetric assay that quantifies liberated inorganic phosphate (P i) upon 2,3-BPG
hydrolysis to 3-PGA. The Pi released from the reaction forms a green complex with the ammonium
molybdate in the malachite green reagent and then is detected spectrophotometrically at an
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absorbance of A620 nm. The concentration of phosphate is then calculated using a P i calibration
curve (Figure 13).

Figure 13. The principle of the malachite green assay.

The phosphatase activity of BPGM is inherently low, and as a result, the potent
phosphatase activator, 2-PG, has frequently been used for its detection.8,171 Thus, BPGM
phosphatase activity will be determined in the presence and absence of 2-PG.
A time-dependent assay was first performed to select the optimum assay duration. The
reaction was left for 80 min, and every 10 min, an aliquot of the assay mixture was taken and the
absorbance for the released Pi was measured as per assay protocol.
The non-activated phosphatase showed a slower reaction compared to the 2-PG activated
reaction (Figure 14). From the time-dependent experiment, the duration of the assay was set within
the linear range of the activity. Therefore, the assay time duration for the non-activated reaction
was set to 50 min, while the 2-PG activated assay time duration was set to 20 min (Figure 14).
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Figure 14. Time-dependent of BPGM phosphatase activity in the presence and absence of 2-PG.

BPGM phosphatase activity was measured using varying enzyme concentrations (0.6-10
M), and the result showed a direct relationship between the velocity and the enzyme
concentrations for both non-activated and activated phosphatase reactions (Figure 15, 16).
Conditions that yield linear results with respect to time and enzyme concentration were used for
the enzyme steady-state kinetic analysis. All subsequent phosphatase assays were performed using
5 M as a standard BPGM concentration in the non-activated reaction and 2 M in the 2-PG
activated reaction.
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The phosphatase activity of the enzyme was measured in the presence and absence of 2PG, and the activity was defined as µmole Pi released per min. In the presence of 5 μM 2-PG, the
phosphatase activity was enhanced to 1.3 µmole Pi/min compared to the control (non-activated
phosphatase, without 2-PG) of 0.18 µmole Pi/min (Table 2).
The Km value of 2,3-BPG for the enzyme in the non-activated reaction was 97 ± 7 μM and
the Vmax was 0.2 µmole Pi/min using 5 µM BPGM (Table 2, Figures 17). The apparent Km and
Vmax for the activated reaction (in the presence of 5 µM 2-PG) were 39 ± 13 M and 0.7 µmole
Pi/min respectively using 2 µM BPGM (Table 2, Figure 18).
In summary, the malachite green assay is considered to be a direct, fast assay that can be
easily adopted for high-throughput screening of BPGM phosphatase activators.
Table 2. BPGM phosphatase activity and steady-state kinetic parameters in the presence
and absence of 2-PG.
Enzyme activity

Km, μM

µmole Pi /min
Control

Vmax,

kcat, min-1

µmole Pi/min

0.200 ± 0.003

97 ± 7

0.20 ± 0.04

0.04 ± 0.02

1.30 ± 0.03

39 ± 13

0.7 ± 0.2

0.3± 0.1

(without 2-PG)

With 5µM 2-PG
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Figure 17. Michaelis-Menten plot of 2,3-BPG on the phosphatase reaction velocity in
the absence of 2-PG.

Figure 18. Michaelis-Menten plot of 2,3-BPG on the phosphatase reaction
velocity in the presence of 2-PG.
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3.2.2.

Kinetic

characterization

of BPGM phosphatase activity and

optimization of PGK•GAPDH•BPGM coupled phosphatase assay

A second assay used to study the BPGM phosphatase activity is the PGK•GAPDH•BPGM
phosphatase coupled enzymatic assay in which the BPGM phosphatase activity is coupled with
Phosphoglycerate kinase (PGK) and GAPDH enzymes activities that is detectable
spectrophotometrically at absorbance of A340 nm. The overall reactions of the assay are as follow:

The assay reaction starts with the hydrolysis of 2,3-BPG by BPGM into 3-PGA (Reaction
1), which is the substrate for the PGK. In the presence of ATP, PGK consumes 3-PGA and ATP
to catalyze the formation of 1,3-BPG and ADP (Reaction 2). The formed 1,3-BPG is then
hydrolyzed by GAPDH into GAP with subsequent oxidation of NADH to NAD detected at A 340
nm (Reaction 3). The phosphatase activity of BPGM is directly proportional to NADH oxidation,
which can be observed as a reduction in NADH absorbance at 340 nm as the reaction progresses.
From the phosphatase reaction progress curve, the duration of the assay was set to 30 min
in the absence of 2-PG, and 10 min in the presence of 2-PG. BPGM phosphatase activity was
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studied with various concentrations of BPGM (1-10 μM) and the results showed a linear
dependence of the reaction velocity with the enzyme concentrations (Figure 19).
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Figure 19. Linear dependence of the non-activated phosphatase reaction velocity on
enzyme concentration.

The phosphatase activity at saturating concentration of 2,3-BPG (0.8 mM) in the presence
and absence of 2-PG was measured, and the results are summarized in (Table 3). The results show
that the phosphatase activity using 5 μM BPGM in the absence of 2-PG was 0.03 µmole of
NADH/min. In the presence of 10 µM 2-PG, the phosphatase activity was stimulated to 0.3 µmole
NADH/min. These values can be compared with the data obtained using the malachite green assay
that showed an activity of 0.2 µmole Pi/min in the absence and 1.3 µmole Pi/min in the presence
of 5 µM 2-PG (Table 2).
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The Km value of 2,3-BPG for the enzyme in the absence of 2-PG was 77.9 ± 1.7 μM and
the Vmax was 0.2 µmole NADH/minute (Table 3). These values compare with the Km and Vmax of
97 ± 7 μM and 0.2 µmole Pi/min, respectively using the malachite green assay (Table 2). The
apparent Km (Km app) of 2,3-BPG in the presence of 10 μM 2-PG decreased to 43±3 μM and Vmax
stimulated to 0.34 µmole NADH/min (Table 3). These compare to 39±13 μM and 0.7 µmole
Pi/min, respectively using the malachite green assay (Table 2). The two assays resulted in similar
kinetic values.
The GAPDH.PGK.BPGM coupled assay was validated by testing the stimulating effect of
2-PG on BPGM phosphatase activity. This assay will be used for drug screening as a secondary
(confirmatory) assay to the malachite green assay, which will be the primary assay.

Table 3. BPGM phosphatase activity and steady-state kinetic parameters in the presence and
absence of 2-PG.
Enzyme activity

Km, µM

µmole NADH/min

Vmax,

kcat, min1

µmole NADH/min

Control

0.030 ± 0.003

77.9 ± 1.7

0.2 ± 0.1

0.05 ± 0.01

With 10 µM 2-PG

0.30 ± 0.01

43 ± 3

0.34 ± 0.01

0.340 ± 0.002
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Figure 20. Michaelis-Menten plot of 2,3-BPG on the phosphatase reaction velocity in
the absence of 2-PG.

Figure 21. Michaelis-Menten plot of 2,3-BPG on the phosphatase velocity in the presence
of 2-PG.
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3.3. Specific Aim 1C: Understand the activation mechanism of 2-PG on BPGM
phosphatase activity using the GAPDH.PGK.BPGM coupled assay
2-PG is the most potent physiological activator of BPGM phosphatase activity. 154 The
exact activation mechanism of 2-PG is poorly understood. Achieving a full understanding of the
activation mechanism would help future efforts in the design of mechanism based BPGM
modulators. Therefore, the activation mechanism of 2-PG for phosphatase activity was studied
using the PGK•GAPDH•BPGM coupled phosphatase assay. Data were plotted for MichaelisMenten nonlinear regression using GraphPad prism software. The Michaelis-Menten plot showed
a pattern that best fits the noncompetitive inhibition model, in which both Km, and Vmax values
changed with increasing concentration of 2-PG from 10 – 1000 µM (Figure 22).

Figure 22. Michaelis-Menten nonlinear regression plot of substrate-velocity curves at five
different activator concentrations.
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The apparent kinetic constants were determined for each 2-PG concentration, and the
results are summarized in Table 4.

Table 4. Enzyme kinetic parameter of 2,3-BPG hydrolysis by BPGM phosphatase in the presence
of 2-PG.
Vmax, µmole NADH/min

Km app (2,3-BPG), µM

kcat, min-1

(± SD)

(± SD)

(± SD)

0

0.2 ± 0.1

77.9 ± 1.7

0.05 ± 0.01

10

0.45 ±0.06

42 ±18

0.18 ±0.02

50

0.98 ±0.03

103 ±14

0.40 ±0.01

250

1.66 ±0.27

133 ± 30

0.7 ±0.1

500

2.0 ±0.17

225 ±80

0.88 ±0.07

1000

2.8 ±0.3

267 ±55

1.12 ±0.11

[2-PG], µM

The kinetics constants results (Table 4) showed that the affinity of 2,3-BPG to BPGM
increased with the addition of 10 µM concentration of 2-PG (Km app 42 µM) compared to the Km
value of 2,3-BPG in the absence of 2-PG (Km 77.9 µM). Interestingly, as the concentration of 2PG increased beyond 10 µM, the affinity of 2,3-BPG to the enzyme starts to decrease from Km app
of 103 µM (at 50 µM concentration of 2-PG) to Km app of 267 µM (at 1000 µM concertation of 2-

50

PG) (Figure 23). The kcat and Vmax, however, increased linearly with increasing 2-PG
concentrations (Figure 23).
The decrease in the Km app of 2,3-BPG value at low 2-PG concentration may suggest
noncompetitive activation by binding of 2-PG to an allosteric or non-catalytic binding site. By
contrast, the increase in the Km app of 2,3-BPG observed at high 2-PG concentrations may indicate
competition between 2-PG and 2,3-BPG at the active site, and one would have expected that the
competition with 2,3-BPG would decrease the Vmax and kcat values. However, both the Vmax and
kcat values were increased even in the presence of saturating 2,3-BPG concentration. This
phenomenon can be explained by the binding of 2-PG to an allosteric or non-catalytic site at low
activator concentration, while the enzyme is already bound to the substrate at the active site.
However, as the concentration of 2-PG increases, 2-PG begins to compete with the substrate at the
active site of the second monomer, resulting in the increase in the rate of 2,3-BPG hydrolysis on
the active site of the first monomer.
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Figure 23. (A) The relationship between the Vmax and 2-PG concentrations (B) The relationship
between the apparent Km and 2-PG concentrations (C) The relationship between the apparent kcat
and 2-PG concentrations.

3.4. Discussion
3.4.1.

BPGM synthase activity

The synthase activity is the main enzymatic activity of BPGM, and it proceeds with
phosphorylation of His11 in the BPGM active site by the acyl phosphate substrate, 1,3-BPG.8,166
Following, the phosphoenzyme transfers the phosphoryl group to an acceptor molecule of 3-PGA
to synthesize 2,3-BPG.8,9

1,3-BPG + 3-PGA

2,3-BPG + 3-PGA

The synthase activity of BPGM was studied using a continuous coupled assay that coupled
the BPGM activity with NADH production by GAPDH. The BPGM substrate, 1,3-BPG, is
commercially unavailable as it is unstable and rapidly converts to 2,3-BPG, is synthesized in situ
during the assay. GAPDH was therefore used to synthesize 1,3-BPG from a mixture of GAPDH,
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GAP, and NAD. Also, the addition of 3-PGA to the reaction mixture of the assay was reported to
be a requirement to maximize the synthase activity.166 Hence, a concentration of 40 µM of 3-PGA
was used in the assay, which is close to its physiological concentration (50-80 µM).183
The synthase activity in our analysis was 0.07 µmole of NADH/min with specific activity
of 8 µmole of NADH/min/mg, which is 2-fold lower than the reported specific activity of 16
U/mg.172,179 This difference may be due to different protein stock, different assay conditions or
different 3-PGA concentrations used in the assay. The concentration used in our assay was 40 µM,
while the reported assay used 100 µM.179
The physiological activator of BPGM phosphatase activity, 2-PG, has been reported to
inactivate the synthase activity at high millimolar concertation.7 During our study we also observed
such inhibition with 1 mM concentration of 2-PG as the synthase activity decreased from 0.07
µmole of NADH/min to 0.03 µmole of NADH/min. The inhibitory effect of 2-PG of the synthase
activity was reported to be due to its binding at the active site; preventing binding of the phosphate
acceptor, 3-PGA. Since the bound 2-PG does not accept phosphate molecule, it is going to
stimulate the dephosphorylation of the phosphoenzyme to a neighboring active water molecule. 166
Also, based on our kinetic analysis of the 2-PG activation mechanism for phosphatase activity, we
speculate that because the 3-PGA physiological concentration (50-80 µM) is higher than the 2-PG
concentration (2-5 µM), 2-PG noncompetitively inhibits the synthase activity by binding to an
allosteric site, lowering the binding affinity of 3-PGA, and stimulating the dephosphorylation of
the phosphoenzyme. Thus, it inhibits the synthase activity.
The GAPDH•BPGM synthase assay has limitations in terms of studying the steady- state
kinetics of the synthase activity. Michalis Menten kinetics for 1,3-BPG could not be obtained
because of the unavailability and instability of this substrate. Also, the 1,3-BPG synthesized in situ
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is not pure and might be mixed with 3-PGA, which could affect the accuracy of the kinetic analysis.
However, regardless of the limitations, this assay can still be used to test the activity of the enzyme
and the effect of modulators on the enzymatic activity.

3.4.2.

BPGM phosphatase activity

The phosphatase activity of BPGM is inherently low unless activated by anions and 2PG.154,166 The unstimulated phosphatase activity has been reported to be 1000-fold lower than the
synthase activity of the enzyme.171 BPGM hydrolyzes 2,3-BPG into 3-PGA and Pi under certain
physiological conditions to ensure regulation of 2,3-BPG level in the erythrocytes. In the literature,
the phosphatase activity of BPGM was studied using radiolabeled activity assay and coupled
enzymatic assay.170,172,179,184 In this work, BPGM phosphatase activity was measured using the
previously reported PGK•GAPDH•BPGM coupled assay, and a non-radioactive malachite green
colorimetric assay.

3-PGA + Pi

2,3-BPG + H2O

The malachite green assay is a well-established colorimetric assay that is used to quantify
Pi released from phosphatase hydrolysis reaction. The assay is direct, fast and sensitive as it can
detect as low as 1.6 picomoles of phosphate in the reaction mixture (Malachite Green assay kit;
Sigma Aldrich). While the radioactive assay is also effective and sensitive, the use of radiolabeled
substrates is expensive, and requires a laborious biochemical extraction and purification procedure
for the protein substrate complex. Hence, the malachite green assay is considered the faster and
cheaper alternative to the radioactive assay and it has an advantage as it can be adopted for high
throughput screening.
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The stimulation with low concertation of 2-PG (5 µM) resulted in 7-fold activation of the
phosphatase activity (0.2 vs. 1.3 µmole Pi /minute) (Table 2). The Michalis Menten kinetics for
2,3-BPG in our analysis showed a Km value of 97 ± 7 µM and 39 ± 13 µM, in the absence and
presence of 5 µM 2-PG, respectively (Table 2). The Vmax also increased from 0.20± 0.04 to 0.70
± 0.12 µmole Pi/minute (corresponding to kcat of 0.04 ± 0.02 to 0.30± 0.01 minute -1) in the absence
and presence of 5 µM 2-PG (Table 2).
The second assay, the PGK•GAPDH•BPGM coupled enzymatic assay, was used as a
secondary assay to test the kinetics of the phosphatase activity by coupling it to the two enzymes
PGK and GAPDH. During the reaction, PGK converts 3-PGA (produced from the hydrolysis of
2,3-BPG by BPGM) to 1,3-BPG and regenerates ADP. GAPDH then consumes 1,3-BPG to
oxidize NADH to NAD, which is measured spectrophotometrically by a decrease in the
absorbance signal at 340 nm. Compared to the malachite green assay, this assay requires a higher
concentration of enzyme and substrate for the activity to be detected. In the literature, this assay
has always been carried out using 2-PG activation conditions.170,179
Our study showed that phosphatase activity of 2,3-BPG hydrolysis in the absence of 2-PG
was 0.030 ± 0.003 µmole NADH/minute and it increased by 10-fold to 0.30± 0.01 µmole
NADH/minute in the presence of 10 µM 2-PG, clearly suggesting 2-PG to be an activator of the
phosphatase activity (Table 3). The Km, Vmax and kcat values of 2,3-BPG hydrolysis are listed in
Table 3. Expectedly, BPGM affinity for 2,3-BPG increased from 77.9 ± 1.7 µM to 43 ± 3 µM in
the absence and presence of 10 µM 2-PG, respectively. Likewise, there was a concomitant increase
in Vmax value from 0.2 ± 0.1 to 0.34± 0.01 (kcat 0.05 ± 0.01 to 0.34 ± 0.002 minute-1), respectively
(Table 3).
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It is worth noting that steady-state kinetic parameters of the BPGM phosphatase activity in
the literature vary widely depending on the assay type and condition. For example, the nonactivated Km of 2,3-BPG has been reported as 7 M by Yu et al.,184 160±8 M by Calvin et al.,170
and 3.5 mM by Garel et al.171 The Km of 2,3-BPG in the 2-PG activated system has also been
reported to be 0.6 µM (with 20-60 M 2-PG) by Rose and Liebowitz,154 25 M (with 50 M 2PG) by Ravel et al.,174 41-71 M (with 1 mM 2-PG) by Calvin et al.,170,171 and 25 µM (with 1.2
mM 2-PG) by Rose.185 The apparent Vmax also varies over a 500-fold range.154
The results from the malachite green and PGK•GAPDH•BPGM assays used in this study
also showed some significant variation to the published values above. However, the results
obtained from both the malachite green assay and PGK•GAPDH•BPGM assays were within an
acceptable range as the Km for 2,3-BPG in the non-activated reaction was 97 M and 77 M,
respectively. While in the 2-PG activated system, K m for 2,3-BPG was 39 ± 13 (with 5 M 2-PG
in malachite green assay) compared to 43 ± 3 M (with 10 M 2-PG in the coupled assay).
In conclusion, the malachite green assay will be used as a primary assay for the drug
screening experiments and the PGK•GAPDH•BPGM coupled assay will be used as a confirmatory
secondary assay.
3.4.3.

2-Phosphoglycolate activation mechanism of BPGM phosphatase

activity
BPGM Phosphatase activity is activated by several anions such as chloride, phosphate,
sulfite, and most potently, 2-PG.152,154 The activators’ binding mode and their activation
mechanisms are not clearly elucidated in the literature.152,154,167 The anion activated phosphatase
activity showed a complex activation mechanism. Chloride and phosphate are known to stimulate
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the phosphatase activity individually or in combination.154 The activation by chloride and
phosphate was competitively inhibited by low concentrations of 3-PGA suggesting the binding of
anions in the active site.154 In addition, the kinetic analysis of chloride activation in the presence
of 2-PG showed that chloride acts as a noncompetitive inhibitor with respect to 2-PG activation.157
Moreover, the kinetic analysis of phosphate activation in the presence of 2-PG showed a
competitive inhibition against 2-PG activation.154 It is noteworthy that the kinetic analysis of the
phosphatase activation by phosphate alone suggested the existence of two binding sites for the
phosphate, yet the second site location is yet to be determined.154 Whether the binding of 2-PG is
in the active site or in the second undetermined site is not conclusive.154
Our kinetic analysis demonstrates that the activation mechanism by 2-PG has a mixed
behavior, a combination of noncompetitive and competitive mechanism, which is in agreement
with our crystallographic studies of BPGM in complex with 2-PG that will be discussed in chapter
4. In the co-crystal structures of BPGM with 2-PG, we observed two binding sites for 2-PG, one
at the active site and the other at the dimer interface. Below, the activation mechanism of 2-PG is
analyzed in terms of the inhibition kinetic model.
Different types of inhibitors are known to affect enzyme inhibition kinetics. Competitive
inhibitors, which are in most instances structurally and chemically similar to the substrates, bind
similarly as the substrate to influence the substrate binding affinity, but not the reaction velocity,
which remains unchanged. In contrast, non-competitive inhibitors are usually structurally different
from the substrates, binding at different site from the substrate site, resulting in reduction in the
enzyme activity, while keeping the substrate binding affinity unchanged. Uncompetitive
inhibitors, however, bind to the enzyme-substrate complex, influencing both the binding affinity
of substrate and the catalysis of the reaction. There is a more complex system called mixed
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inhibition that covers a wide range of behavior as it can result in competitive/noncompetitive or
competitive/uncompetitive kinetics.
By analogy to the inhibitor model, the apparent increase in the binding affinity of 2,3-BPG
with low 2-PG concentration (10 µM) with concomitant increase in Vmax and kcat (Table 4) is
considered as noncompetitive activation, in which 2-PG binds to the enzyme at a site distinct than
the substrate active site. However, the linear decrease in 2,3-BPG binding affinity with increasing
2-PG concentrations suggests a competitive mechanism at the active site (Figure 23B).
Nevertheless, instead of the expected decrease in Vmax and kcat that usually happens during the
competition of any ligand with the substrate at the active site, both Vmax and kcat values were
observed to be increasing (Figure 23A and C). This observation is explained by the competition
of 2-PG with the substrate binding at the active site of one monomer, rendering only the active site
of the other monomer stimulated. On this basis, the activation mechanism was considered as mixed
type activation, a hybrid of noncompetitive and competitive behavior. The mixed activation is
complex to analyze and involves the activator binding to both free enzyme and enzyme-substrate
complex with the activator having more affinity to one binding state over another. In our case, we
postulate that 2-PG preferentially binds to the enzyme-substrate complex over the free enzyme
since the physiological concentration of 2-PG is low (2-5 µM).186,187 At present, this is a working
mechanism, and additional research and experiments are required to elucidate the precise
mechanism of this activation.

58

CHAPTER 4

4. SPECIFIC AIM 2: Pursue X-ray crystallography studies to elucidate the atomic
binding of 2-PG, 2,3-BPG and/or citrate with BPGM

X-ray crystallography is a powerful tool in structural biology and structure-based drug
design. X-ray crystallography is used to determine the three-dimensional structure of small
molecules, biological macromolecules and their complexes with other molecules. X-ray
crystallography is also used as a tool in elucidating or understanding the function and mechanisms
of macromolecules.188
X-ray crystallography has been used to study BPGM in its unliganded form and in complex
with its substrates (2,3-BPG and 3-PGA) to elucidate the enzyme reaction mechanisms, as well as
determine the structural differences with its homologous glycolytic enzyme, phosphoglycerate
mutase (PGAM1).160,161,189,190 In this chapter, structure elucidation of BPGM in complex with the
phosphatase activator, 2-PG in the presence and absence of the substrate, 2,3-BPG, and the
phosphatase inhibitor, citrate, will be presented. The binding mode and interaction of these two
effectors with BPGM will help gain more insights into the mechanism of action of the phosphatase
activity, and importantly help to design and develop potential modulators for BPGM activity for
the treatment of diseases.
As pointed out previously, BPGM is an erythrocyte exclusive multifunctional enzyme
whose main function is to regulate the concentration of 2,3-BPG levels in RBCs through two
enzymatic activities (synthase and phosphatase). The synthase activity of BPGM is responsible for
catalyzing the intermolecular phosphoryl transfer reactions to synthesize 2,3-BPG,8,166 while the
phosphatase activity of BPGM is responsible for the hydrolysis of 2,3-BPG. The phosphatase
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activity of BPGM is low and can be physiologically stimulated by the potent activator, 2-PG.154
The activation mechanism of 2-PG and the mode of binding to BPGM are still not fully understood.
The binding of 2-PG was postulated to be at the substrate active site.174 In chapter 3, we have
analyzed the kinetics of 2-PG activation mechanism, which revealed the activation mechanism of
2-PG to be a mixture of noncompetitive and competitive activation, suggesting the binding of 2PG to the substrate active site and a second binding site. In order to understand the 2-PG stimulated
phosphatase activity on atomic level and to locate the exact binding site of 2-PG, we co-crystallized
the ternary complex of BPGM, 2,3-BPG and 2-PG and the binary complex of BPGM and 2-PG
for structure determination.
The BPGM phosphatase inhibitor, citrate, is a red cell metabolite that has been reported to
maintain erythrocyte 2,3-BPG levels when used as an additive in stored blood.191 Citrate is also
known to be an inhibitor for other metabolic enzymes, such as 6-phosphofructo-2-kinase and
isocitrate dehydrogenase.192 The exact binding mode of citrate to BPGM is unknown,190 however,
it has been proposed to bind at the active site of the enzyme, similar to 2,3-BPG binding mode
since both ligands have similar size and electronic properties,190,193 and the fact that the published
crystal structure of the homologous enzyme PGAM1 showed bound citrate at the active site (PDB
ID 1YFK).193 We therefore undertook structural studies to locate the exact binding site of citrate,
which potentially could serve as target to design BPGM modulators.
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4.1. Results
4.1.1.

Crystallographic study of BPGM in complex with 2,3-BPG and 2-PG

To gain molecular insight into 2-PG activating effect on BPGM phosphatase activity, we
set out to determine the ternary complex structure of BPGM with 2,3-BPG and 2-PG using X-ray
crystallography. For the crystallization experiment, BPGM (30 mg/mL (1 mM)) was incubated
with 3.8 mM 2,3-BPG and 7.6 mM 2-PG for 1 hour. Following, the complex was crystallized using
the condition: 10% v/v Polyethylene glycol 200, 0.1 M BIS TRIS propane (pH 9), and 18%
Polyethylene glycol 8000 (PEGRx 2, Hampton Research). The crystallization condition required
no cryoprotectant. The X-ray diffraction data was collected at 100 K using a Rigaku MicroMax007HF X-ray Generator and Eiger R 4 M Detector. The complex crystallized in the orthorhombic
space group P212121 with cell constant of a=53.07 Å, b=70.86 Å, c=159.8 Å, α=90.0°, β=90.0°,
γ=90.0°. The data set was processed with CrysAlysPro 40.64.42a (Rigaku OD, Yarnton,
Oxfordshire, England, 2015) and the CCP4 suite of programs to a resolution of 2.25 Å.194 The
crystallization parameters are summarized in Table 5.
The crystal structure was determined with Phaser-MR (simple interface) molecular
replacement with the Phenix software package195 using the monomeric structure of BPGM
complexed with 2,3-BPG (PDB ID 2H4Z) as a search model. Two monomeric molecules, forming
the functional dimer were obtained per the asymmetric unit of the crystal. The solved structure
underwent iterative cycles of refinement with the Phenix software along with refinement and
model building using the COOT graphic program.195–197 The current refined structure has Rwork
and Rfree of 20 and 27 % respectively. Detailed refinement parameters are reported in Table 5. The
Ramachandran plot showed 96.3% of the residues are located in the favored area, and 3.5% in the
allowed area with no outliers. As will be described later, even though BPGM was co-crystallized
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with the substrate 2,3-BPG and the effector 2-PG, the resulting complex structure showed the
product 3-PGA (instead of the co-crystallizing substrate 2,3-BPG) and the effector 2-PG bound to
the protein. Hence, the ternary complex structure will be referred to as BPGM•3-PGA•2-PG
complex.
The overall structure of the ternary BPGM•3-PGA•2-PG (Figure 24) is a homodimer with
two identical monomers, A and B, that associate together by a two-fold non-crystallographic
symmetry. There are two active sites that are located at the C-terminus portion of the α/β domain
of each monomer. We observed significant portions of the C-termini of both monomers to be
disordered and/or lack electron density, especially in monomer B. In monomer A, instead of 259
amino acids, we only observed residues from Ser2 to Val254, while in monomer B with more
extensive disorder, we observed residue from Ser2 to Ile241.

Figure 24. Overall structure of BPGM with bound 3-PGA in the active site of
monomer A, 2-PG in the active site of monomer B, and 2-PG at the dimer interface.
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Table 5. Crystallization and refinement parameters of ternary BPGM•3-PGA•2-PG complex
structure.

Data set
Data collection
Resolution range (Å)

BPGM•3-PGA•2-PG

Space group
Unit cell dimensions [a, b, c (Å)]
Unique reflections

P212121
53.07
70.86 159.8
29143 (2912)

26.18 - 2.25 (2.33 - 2.25) Å

R merge (%)1

13.955

Completeness (%)

98.53 (99.04)

Refinement
Rwork

0.20 (0.32)

Rfree2

0.27 (0.3)

r.m.s.d
Bond length (Å)
Bond angles (º)

0.008
1.24

Molprobity statistics
All atom clash score

6.1

Ramachandran plot (%)
Favored
Allowed
Outliers
Rotamer outlier

96.3
3.5
0.2
0.00

Wilson B factor

33.23

1 Rmerge = ΣhklΣi |Ii (hkl) − |/ΣhklΣi Ii (hkl).
2 Rfree was calculated from 5% randomly selected reflection for cross-validation. All other measured
reflections were used during refinement
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The monomer A active site was well defined with a continuous electron density map;
however, the monomer B active site showed significant disorder, in most part due to the lack of
density at the C-terminal region that forms part of the active site. In the well-defined active site of
monomer A, residues Arg100, Arg116, Arg117 (located at the entrance of the active site pocket),
and the C- terminus residue, Gln251, were observed to move closer to the substrate, effectively
closing the active site pocket. However, in monomer B, Arg100, Arg116 and Arg117 were
disordered as evidenced by missing electron density of their side-chains. Moreover, the C-terminus
residues beyond Ile241 were not resolved. It is clear that the active site of monomer B is in an
open conformation while that of monomer A is in closed conformation.
Although, BPGM was co-crystallized with 2,3-BPG, in the monomer A active site, the
electron density of the bound substrate clearly suggested 3-PGA (Figure 25A), which is the
hydrolysis product of 2,3-BPG. Hydrolysis of 2,3-BPG might have taken place during the complex
incubation and/or during the crystallization experiment as observed by the disappearance of the 2phosphoryl group of 2,3-BPG, as well as the unphosphorylated His11 in the active site of monomer
A. As noted above, binding of 3-PGA resulted in a closed active site. Interestingly, in monomer
B, where we observed an open active site conformation with significant disorder, the bound
substrate corresponded to 2-PG (Figure 25B)
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Figure 25. (A) Electron density map of BPGM with 3-PGA bound at monomer A active site. (B)
Electron density map of BPGM with 2-PG bound at monomer B active site. The final 2FoFc refined electron density map contoured at 0.8 σ. Note how R116 and R100 are disordered in
monomer B while ordered in monomer A.
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Atomic interactions of 3-PGA with the active site residues in monomer A (Figure 26A)
were similar to the previously published binary BPGM•3-PGA co-crystal structure by Wang et al.
(PDB ID 2H4X).161 The 3-PGA phosphoryl oxygen atoms (Figure 26A) interact with the
guanidino group of Arg116 and Arg117, the amide of Asn190, and the hydroxyl of Tyr92. In
addition, the phosphoryl oxygen atom forms a direct hydrogen-bond interaction with the guanidino
group of Arg100. The hydroxyl of 3-PGA makes a direct hydrogen-bond interaction with the
carboxyl of Glu89, and a weak interaction with the guanidino group of Arg10. The hydroxyl of 3PGA also interacts with the residues at the bottom of the active site, including His11, Arg62, and
Glu89 through hydrogen-bond interactions mediated by three water molecules. Lastly, the
carboxyl of 3-PGA forms hydrogen-bond interactions with the main-chain nitrogen atoms of Ser24
and Cys23.
Figure 26B depicts the molecular interactions of 2-PG at the active site of monomer B. In
an almost similar fashion to the bound 3-PGA in monomer A, 2-PG phosphoryl oxygen atoms
form hydrogen-bond interactions with the amide of Asn190, the hydroxyl of Tyr92, and the
guanidino group of Arg10. The interactions with the guanidino group of Arg116, and Arg117
observed in monomer A were missing due to the disorder in their side-chains. The carboxyl of 2PG makes direct hydrogen-bond interactions with the guanidine group of Arg100, and the mainchain nitrogen atoms of Cys23 and Ser24. The carboxyl of 2-PG also makes water-mediated
interactions with Glu89, Asn190, and Gly189. However, unlike 3-PGA, 2-PG does not make any
direct hydrogen-bond interactions with Glu89, nor water-mediated hydrogen-bond interactions
with His11 and Arg62 since only one water molecule was found in monomer B.
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Figure 26. (A) Molecular interactions of 3-PGA at the monomer A active site of BPGM. (B)
Molecular interactions of 2-PG at the monomer B active site of BPGM.

In a first of such reports, the ternary co-crystal structure showed 2-PG bound at the dimer
interface of BPGM, close to the two-fold non-crystallographic axis (Figure 27A). The 2-PG makes
interactions with His65 from both monomers, and Glu72 from monomer B. The phosphoryl
oxygen atoms of 2-PG make direct hydrogen-bond interactions with the amide nitrogen of His65
in monomer A, and the oxygen atom of Glu72 in monomer B (Figure 27B). In addition, the
carboxylate of 2-PG interacts through water-mediated interaction with the amide nitrogen atom of
His65 residue in monomer B (Figure 27B).
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Figure 27. (A) Electron density map of BPGM with 2-PG bound at the dimer interface. The final
2Fo-Fc refined electron density map is contoured at 0.8 σ. (B) Molecular interactions of 2-PG at
the dimer interface of BPGM.

4.1.2.

Crystallographic study of BPGM in complex with 2-phosphoglycolate

To confirm the binding mode of 2-PG to BPGM, we undertook a co-crystallization study
of BPGM with 2-PG in the absence of 2,3-BPG. BPGM (30 mg/mL) was incubated with 2-PG
(8.3 mM) for 1 hour. Following, the complex was crystallized using the same condition as
described above for the ternary BPGM•3-PGA•2-PG complex, containing 10% v/v Polyethylene
glycol 200, 0.1 M BIS TRIS propane (pH 9), and 18% polyethylene glycol 8000 (PEGRx 2,
Hampton Research). The crystallization condition required no cryoprotectant Like the ternary
BPGM•3-PGA•2-PG complex, the binary BPGM•2-PG complex also crystallized in the
orthorhombic space group of P212121 with isomorphous unit cell dimension of a=52.61 Å, b=70.95
Å, c=159.2 Å, α=90.0°, β=90.0°, γ=90.0°. Data was collected to a resolution of 2.4 Å. The refined
ternary BPGM•3-PGA•2-PG complex without the bound ligand and water molecules was used as
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a starting model to refine against the BPGM•2-PG complex data. Two molecules that form the
functional dimer were found per asymmetric unit. The structure underwent iterative cycles of
refinement with the Phenix software along with manual refinement and model building using the
COOT program.195–197 Detailed crystallization and refinement parameters are summarized in Table
6.
The overall structure of the binary BPGM•2-PG complex was similar to the above
described ternary BPGM•3-PG•2-PG complex structure. The activator, 2-PG, was observed bound
to the active site of both monomers, A and B, and at the dimer interface of BPGM (Figure 28).

Figure 28. The overall structure of BPGM in complex with 2-PG at the active sites and dimer
interface.
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Table 6. Crystallization and refinement parameters of BPGM•2-PG complex structure.

Data set
Data collection
Resolution range (Å)

BPGM•2-PG

Space group

P212121

Unit cell dimensions [a,b, c (Å)]

52.6

Unique reflections

21758 (2115)
12.85
32.85
99.65 (99.67)

(%)a

R merge
Exposure time
Completeness (%)
Refinement
Rwork

29 - 2.48 (2.569 - 2.48) Å

70.8 159.00

0.21 (0.27)

Rfreeb

0.28 (0.37)

r.m.s.d
Bond length (Å)
Bond angles (º)

0.016
1.57

Molprobity statistics
All atom clash score
Ramachandran plot (%)
Favored
Allowed
Outliers
Rotamer outlier

a

b

9.3
93.29
6.50
0.20
1.8

Rmerge = ΣhklΣi |Ii (hkl) − |/ΣhklΣi Ii (hkl).
Rfree was calculated from 5% randomly selected reflection for cross-validation. All other measured

reflections were used during refinement
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Like the ternary BPGM•3-PGA•2-PG complex, we also detected the absence of residues
from the C-terminus of both monomers, but significant disorder was detected in monomer B as
described above for the ternary BPGM•3-PGA•2-PG complex. Monomer A showed resolved
residues from Ser2 to Val254, while monomer B showed only resolved residues from Ser2 to
Ile245. Like the ternary BPGM•3-PGA•2-PG complex, the monomer B active site showed some
disorder as evidenced by missing side-chain electron density of Arg100, Arg116, and Arg117
(Figure 29B), while monomer A active site was well defined and ordered (Figure 29A).
Also, as described above for the ternary BPGM•3-PGA•2-PG complex, monomer A active
site in the binary BPGM•2-PG complex structure is in close conformation, trapping the 2-PG with
the residues that guard the active site, including Arg100, Arg116, and Arg117, and Gln251 from
the C-terminus (Figure 29A).
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Figure 29. (A) Electron density map of BPGM with bound 2-PG at the active site of monomer B. (B)
Electron density map of BPGM with bound 2-PG at the active site of monomer A. The final 2Fo-Fc refined
electron density map contoured at 0.8 σ.
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Figure 30A represents the molecular interactions of 2-PG at the active site of monomer A.
The 2-PG phosphoryl oxygen atoms make hydrogen-bond interactions with the guanidino group
of Arg100, Arg116, Arg117, the amide of Asn190, and the hydroxyl of Tyr92. In addition, the
phosphoryl oxygen atom forms water-mediated interactions with Asn190, Glu89, Arg10, and a
direct hydrogen-bond interaction with the guanidino group of Arg100. The carboxyl group of 2PG forms hydrogen-bond interactions with the main-chain nitrogen atoms of Cys23 and Ser24,
and the guanidino of Arg100. As noted in monomer A of the ternary complex, two water molecules
were found at the active site, facilitating the interaction between 2-PG and the residues Arg10,
Glu89, Asn190, and Gln251. Unlike 3-PGA, 2-PG does not have a water-mediated interaction with
Arg62 (Figure 30B).

Figure 30. (A) Molecular interactions of 2-PG at the active site of monomer A. (B) Molecular
interactions of 2-PG at the active site of monomer B.
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In monomer B, the phosphoryl oxygen atoms of 2-PG form direct hydrogen-bond
interactions with the amide of Asn190, and the hydroxyl of Tyr92 (Figure 30B). As observed in
monomer B of the ternary BPGM•3-PGA•2-PG complex, the interaction with Arg116, and Arg117
were missing due to disorder. Furthermore, the carboxyl of 2-PG makes hydrogen-bond
interactions with the main-chain nitrogen atoms of Cys23 and Ser24. However, unlike 2-PG in
monomer B of the ternary BPGM•3-PGA•2-PG complex, the carboxyl of 2-PG does not form any
interaction with Arg100. Moreover, in a similar manner to monomer B of the ternary complex, the
water-mediated interactions with the residues at the bottom of the active site, His11, Arg10 and
Glu89, were not observed as the structural water molecules were missing due to disorder. It is clear
that monomer B open site makes fewer interactions with 2-PG compared to the monomer A close
active site.
The binary co-crystal structure also showed 2-PG bound at the dimer interface of BPGM,
close to the two-fold non-crystallographic axis (Figure 31A). It involves direct and water-mediated
interactions between 2-PG and the His65 and Glu72 residues. The phosphoryl oxygen atoms
interact through water-mediated hydrogen-bond interaction with the amide nitrogen atom of His65
residue in monomer A, in contrast to the direct hydrogen-bond observed in the ternary BPGM•3PGA•2-PG complex. The carboxylate of 2-PG, however, makes water-mediated interactions with
only His65 of monomer B, unlike the carboxylate of the ternary BPGM•3-PGA•2-PG complex
that makes water-mediated interaction with both His65 and Glu72 (Figure 31B).
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Figure 31. (A) Electron density map of BPGM with bound 2-PG at the dimer interface with final
2Fo-Fc refined electron density map contoured at 0.8 σ. (B) Molecular interactions of 2-PG at the
dimer interface.

4.1.3.

Crystallographic study of BPGM in complex with citrate

Citrate has been reported to act as a BPGM phosphatase inhibitor. In order to elucidate the
binding interaction of citrate to BPGM, a crystal of the binary BPGM•citrate complex was obtained
with high concentrations of citrate. BPGM at a concentration of (30 mg/mL) was crystallized in
1000 mM Sodium citrate tribasic, 100 mM Sodium cacodylate/hydrochloric acid (pH 6.5) (Wizard
classic 1, Rigaku). A crystal in the orthorhombic space group P21212 space group with unit cell
dimension of a=129.3 Å, b=99.6 Å, c=38.4 Å, α=90.0°, β=90.0°, γ=90.0° was obtained. The
crystal parameter is different from those of the previous two structures (a=52.61 Å, b=70.95 Å,
c=159.2 Å, α=90.0°, β=90.0°, γ=90.0°). The two monomers that form the functional dimer were
seen in the asymmetric unit. Data were collected to a resolution of 2.3 Å. The structure was
determined by Phaser-MR (simple interface) molecular replacement with the Phenix software
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package195 using the monomeric structure of BPGM in complex with 2,3-BPG (PDB ID 2H4Z) as
a search model. Data collection and refinement parameters are summarized in Table 7.
Unlike the above ternary BPGM•3-PGA•2-PG and binary BPGM•2-PG complexes that
showed only significant disorder at the C-terminus of monomer B, the C-terminus of both
monomers of the binary BPGM•citrate complex are equally disordered, missing residues beyond
Gly236. In another significant difference from the previous two structures, the structure of the
binary BPGM•citrate complex showed only a bound citrate in monomer A and not monomer B
(Figure 32). Like BPGM•3-PGA•2-PG and BPGM•2-PG complexes, the BPGM•citrate complex
also showed bound citrate at the dimer interface, in a similar position as the bound 2-PG.

Figure 32. The overall structure of BPGM in complex with citrate at the active site and the dimer
interface.
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Table 7. Crystallization and refinement parameters of BPGM•citrate complex structure.
Data set
Data collection
Resolution range (Å)

BPGM•citrate

Space group
Unit cell dimensions [a,b, c (Å)]

28.68 - 2.3 (2.382 - 2.3) Å
P21212
129.3 99.6 38.4

Unique reflections
R merge (%)a
Completeness (%)

22872 (2263)
15.16
99.83 (100.00)

Refinement
Rwork

0.21 (0.27)

Rfreeb

0.25 (0.35)

r.m.s.d
Bond length (Å)
Bond angles (º)

0.008
1.01

Molprobity statistics
All atom clash score

8.72

Ramachandran plot (%)
Favored
Allowed
Outliers

95.68
4.10
0.22

Rotamer outlier

0.47

a

Rmerge = ΣhklΣi |Ii (hkl) − |/ΣhklΣi Ii (hkl).

b

Rfree was calculated from 5% randomly selected reflection for cross-validation. All other

measured reflections were used during refinement

77

Another significant difference from the ternary BPGM•3-PGA•2-PG and binary BPGM•2PG complex structures is that monomer A of BPGM•citrate complex with the bound citrate was
in a partially closed conformation due to disorder at the C-terminus region (Figure 33A). The
atomic interactions of citrate at the active site of monomer A showed that one carboxylate group
makes direct hydrogen-bond interactions with guanidino of Arg116, amide of Asn190, hydroxyl
of Tyr92 (Figure 33B). The second carboxylate group makes hydrogen-bond interactions with the
guanidino of Arg10. Similarly, the third carboxylate group makes hydrogen-bond interactions with
the guanidino of Arg100, and its main chain nitrogen with Ser24, Cys23 (Figure 33B). The sidechain of Arg117 was disordered, making it difficult to locate its actual orientation. As noted above,
the missing C-terminus residues beyond Gly236 resulted in a partially closed active site
conformation, which is in contrast to the ternary BPGM•3-PG•2-PG and binary BPGM•2-PG
complex structures that were characterized by closed active sites in monomer A. No structural
water molecules were found at the active site of monomer A. In monomer B, no apparent bound
citrate was found, and the side-chain of several residues in the active site, including Arg100,
Arg116, and Arg117 were disordered as evidenced by lack of electron density.
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Figure 33. (A) Electron density map of BPGM with bound citrate at the active site of monomer A with the final
2Fo-Fc refined electron density map contoured at 0.8 σ. (B) Molecular interactions of citrate at the active site
of BPGM.
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The bound citrate at the dimer interface is involved in direct hydrogen-bond interactions
with His65 and Glu72 from both monomers (Figure 34A and B). It also makes water-mediated
hydrogen-bond interaction with His65 of monomer A and a direct hydrogen-bond interaction with
His65 of monomer B. In addition, citrate has direct hydrogen-bond interactions with Glu72 of both
monomers. It appears that citrate makes more interactions at the dimer interface than 2-PG in the
ternary BPGM•3-PGA•2-PG or binary BPGM•2-PG complex structures.

Figure 34. (A) Electron density map of BPGM with bound citrate at the dimer interface of BPGM
with the final 2Fo-Fc refined electron density map contoured at 0.8 σ. (B) Molecular interactions
of citrate at the dimer interface of BPGM.
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4.1.4.

Identification of allosteric sites on BPGM surface using FTMap

A computational solvent mapping tool was utilized using the FTMap online server
(http://ftmap.bu.edu/) to search for potential binding sites, including allosteric sites on the BPGM
surface, and to assess their druggability.198,199 FTMap mimics the multiple solvent crystal
structures (MSCS) approach, which is a crystallographic fragment screening method. However,
FTMap uses a fast Fourier transform (FFT) algorithm for fragment screening. This method is based
on the premise that fragment screening identifies hotspots or consensus sites (CSs), which are
regions on the protein surface that contribute highly with binding interactions between protein and
ligand, by identifying the sites where clusters of different fragments or probes bind.198,199 The site
with the highest number of probes and clusters is likely considered to be druggable.198,199
The unliganded crystal structure of BPGM (PDB ID 3NFY) was uploaded to the server for
analysis. FTMap then docked the entire protein surface with 16 small molecular probes including,
ethanol, isopropanol, isobutanol, acetone, acetaldehyde, dimethyl ether, cyclohexane, ethane,
acetonitrile, urea, methylamine, phenol, benzaldehyde, benzene, acetamide, and N,Ndimethylformamide, with millions of different poses to identify the most energetically favorable
binding pose for each probe. Next, each probe type was clustered into CSs according to their
average free energy. The CSs are then ranked on the basis of the number of probe clusters bound,
with the highest number of probe clusters predicting a primary hot spot.200 The output result in the
form of protein structure with bound probe clusters can be visually inspected using PyMOL
(Figure 35A). The result also includes two contact bar graphs, displaying the contact rate of each
residue with the probe molecules as a percent of total contacts. The first graph (Figure 35B)
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corresponds to the hydrogen-bond interaction and the second graph (Figure 35C) is for other nonbonded interactions.
The result showed the existence of seven CSs (Figure 35A). The dimer interface site,
denoted as CS0, was predicted to be the top-ranked site with the highest number of bound probes,
which equaled to 19 molecular probes. Notably, the binding of at least 16 molecular probes is a
requirement for a site to be druggable.200 The second predicted site, denoted as CS1, located at the
substrate active site of monomer A was found bound to 13 molecular probes (Figure 35A). The
third and fourth sites, CS2, and CS3 were found bound to 12 molecular probes and are located at
a site surrounded by Val59, Trp78, Ser84 Arg141, and Cys145, and at the active site of monomer
B, respectively. The remaining sites CS4, CS5, and CS5 have lower number of probe clusters
bound to each site, suggesting low druggability (Figure 35A).200
The first contact graphs showed His65 from both monomers and Tyr92 from monomer A
participating in the highest number of hydrogen-bond interactions with the probe molecules
(Figure 35B). The second contact graph demonstrated Trp68 from monomer A, followed by Phe22
from monomer A, and Trp68 from monomer B with the highest percentage of non-bonded contact
score with the probe molecules (Figure 35C). All residues, His65, Tyr92, Trp68, and Phe22, are
located at CS0, the dimer interface site, which clearly support the crystallographic studies that
indicate the dimer interface site to be a potentially druggable site.
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Figure 35. FTMap output (A) Bound probe molecules to consensus sites on unliganded
BPGM surface (PDB ID 3NFY); CS0 (cyan, 16 probe clusters), CS1 (magenta, 13), CS2
(yellow,12), CS3 (wheat, 12), CS4 (white, 8), CS5 (purple, 8), and CS6 (orange, 7). (B) Contact
graph for hydrogen-bond interactions (C) Contact graph for nonbonded residue interactions.
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4.2. Discussion
4.2.1.

Overall structure comparison of the unliganded BPGM, binary

BPGM•2-PG complex and ternary BPGM•3-PGA•2-PG complex
The crystal structures of BPGM complexed with the activator 2-PG, as well as complexed
with 2-PG and 2,3-BPG have been determined to resolutions of 2.4 and 2.25 Å, respectively. The
former structure showed a binary BPGM•2-PG complex, while the latter showed a ternary
BPGM•3-PGA•2-PG complex. It became clear that that 2,3-BPG was hydrolyzed to the product
3-PGA during the crystallization of the ternary complex. Both structures were found to be missing
the initiating methionine residue. Monomer A of the ternary BPGM•3-PGA•2-PG and binary
BPGM•2-PG crystal structures showed resolved residues from Ser2 to Val254, while monomer B
only showed resolved residues from Ser2 to Ile241, and Ser2 to Ile245, respectively. The Cterminus residues beyond Gly236 residues were disordered as evidenced by weak electron density,
while residues beyond 241 of the ternary BPGM•3-PGA•2-PG and 245 of the binary BPGM•2-PG
complexes were completely missing in the electron density.
The active site of monomer B also showed some disorder, especially with the side-chain
of Arg100, Arg116, Arg117 located at the mouth of the active cleft. These residues are highly
flexible and have been shown to exhibit significant movements, particularly Arg117, during
substrate binding.190 The movement of these residues upon substrate binding along with their
interaction with the C-terminal tail residues helps maintain the active site in a catalytically active
closed conformation.
It is also noteworthy that the C-terminus is a conserved domain in the homologous
phosphoglycerate mutase enzyme 1 (PGAM1) and have been demonstrated to play an important
role in the functional activities of the enzymes, including binding of substrates, stabilization of the
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phosphorylated enzyme intermediate, and the release of the product by transitioning between open
and closed conformations of the active site.201,202 The deletion of a minimum of seven residues at
the C-terminus portion has been shown to abolish the three catalytic activities of BPGM (synthase,
phosphatase, and mutase).159
The disorder observed at the C-terminus of BPGM is well documented in the literature due
to the dynamic nature and high degree of flexibility of this region. When the C-terminus is resolved
as observed in monomers A of the ternary BPGM•3-PGA•2-PG complex, and the binary BPGM•2PG complex, as well as in the previously published structures of BPGM in complex with 2,3-BPG
(PDB ID 2H4Z), and BPGM in complex with 3-PGA (PDB ID 2H4X),161 the side-chain of Gln251
is observed to be directed toward the center of the active site pocket making interactions with the
bound substrate, as well as with Arg100 and Arg116.160 These interactions help constrain the
flexibility of Arg100 and Arg116 side-chains, and fix the active site into a closed conformation,
which is required for catalysis.160 Expectedly, absence of the above described Gln251-mediated
interactions with Arg100 and Arg116 in monomers B of the ternary BPGM•3-PGA•2-PG and
binary BPGM•2-PG complex structures, as well as in both monomers of the binary BPGM•citrate
complex structure, have led to significant disorder of the C-termini, resulting in open active site
conformations in these structures. Also, expectedly, BPGM structures without bound substrate or
ligand at the active site, e.g., the unliganded structure of BPGM (PDB ID 3NFY),190 has C-termini
disorder with open active site conformations. Similar observations have been reported for the
unphosphorylated/unliganded form of the homologous PGAM1 enzyme as the last 9 residues of
the C-terminal tail were found to be missing electron density.160 These observations showed that
the unphosphorylated and/or the unliganded state of the enzyme exhibits more disordered Cterminus residues than the bound or reacting conformation of the enzyme, where the C-terminal
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residues are found well defined and covering the active site and maintaining the catalytically
active conformation. It is also clear that not all bound ligands at the active site led to resolution of
the C-termini or closed active site conformation as observed in monomer B of the ternary
BPGM•3-PGA•2-PG complex, monomer B of the binary BPGM•2-PG complex, and both
monomers of the binary BPGM•citrate complex.
Quite interestingly, the ternary BPGM•3-PGA•2-PG and the binary BPGM•2-PG
complexes revealed a novel binding site for 2-PG at the dimer interface. It thus appears that 2-PG
is capable of binding to both the active site and a non-catalytic site at the dimer interface. The
bound 2-PG at the dimer interface specifically makes interactions with His65 residues from both
monomers and Glu72 from monomer B, that may potentially affect monomer-monomer
cooperativity, either by stabilizing or destabilizing the monomer-monomer contact. Interestingly,
the existence of an alternative binding site for 2-PG is in agreement with our kinetic analysis of
the 2-PG activation mechanism reported in chapter 3. Our results showed that 2-PG exhibits a
mixed noncompetitive and competitive mechanism suggesting the binding of 2-PG to the active
site as well to an alternative modifier site. The latter appears to be at the dimer interface.
Interestingly, a chloride ion was reported bound at the dimer interface (near the 2-fold axis)
of PGAM1 in complex with citrate (PDB ID 1YFK), interacting with Trp68 and Arg83. 193
Chloride ions have been demonstrated to activate the phosphatase activity of the PGAM1 enzyme
as well as BPGM as observed by lowering the apparent K m of 2,3-BPG.154,203 In the PGAM1,
chloride has also been shown to be a competitive inhibitor to the activation of 2-PG. Thus, it was
postulated that 2-PG and chloride bind to an alternative undetermined site separate from the
substrate active site.203
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Binding of 2-PG at the dimer interface appears not to induce any significant conformational
changes at the interface region as observed by low RMSD value of ~0.4 Å when the dimer interface
of the unliganded BPGM structure (PDB ID 3NFY) was superposed with the dimer interface of
the ternary BPGM•3-PGA•2-PG complex and binary BPGM•2-PG complex structures. Similarly,
the RMSD was ~0.3 Å, when the dimer interface of the unliganded BPGM structure was
superposed with the BPGM•3-PGA (PDB ID 2H4X) and BPGM•2,3-BPG (PDB ID 2H4Z)
complex structures. Note that, unlike 3NFY, 2H4X and 2H4Z, our liganded structures contain
bound 2-PG ligand at their dimer interface. It appears that 2-PG binding at the dimer interface
causes a long-range effect at the active site of the second monomer. Both active sites in 2H4X and
2H4Z are in the closed conformation, the former with 2,3-BPG bound in both active sites, and the
latter with 3-PGA bound in both active sites. Our two structures with a bound ligand at the dimer
interface, even though show both active sites occupied by ligands, only monomer A is in the closed
conformation, while monomer B is in the open.
Interestingly, in the ternary BPGM•3-PGA•2-PG complex we only observed 3-PGA bound
to monomer A active site, with 2-PG bound to monomer B active site. From the foregoing, it
appears that the binding at the dimer interface exerts changes in the dynamics of the protein, and
the flexibility of the active site residues, both of which can affect the binding affinity of the
substrate in the second subunit without significant conformational changes at the dimer interface
region. This is the first such crystallographic report of a dimer interface binding.
4.2.2.

Active site comparison of the unliganded BPGM and ternary

BPGM•3-PGA•2-PG complex
As previously mentioned, 3-PGA binds in the active site of monomer A in the ternary
BPGM•3-PGA•2-PG complex structure. Structural water molecules were observed mediating and
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strengthening the interactions between the bound 3-PGA and the active site residues Arg10, His11,
Glu13, Arg62, Glu89, and His188. These water-mediated interactions are missing in monomer B
with the bound 2-PG, in part due to disorder. Similarly, in monomer A of the binary BPGM•2-PG
structure, 2-PG was observed to interact with the active site residues through two structural water
molecules. While in monomer B, the binding of 2-PG was weak and no structural water molecules
were found to facilitate the interactions with the residues at the bottom of the active site. It is clear
that the two monomers of the ternary BPGM•3-PGA•2-PG complex and binary BPGM•2-PG
complex bind to substrates with different affinities.
Close inspections of the active site of monomer A of the ternary BPGM•3-PGA•2-PG and
binary BPGM•2-PG complexes in comparison with the active site of monomer A of the unliganded
structure (PDB ID 3NFY) suggested that binding of substrate leads to significant movement of the
loop from His11 to Ser24 at the bottom of the active site pocket toward the substrate (Figure 36A
and B). In addition, the side-chain of Glu13 of the ternary BPGM•2,3-BPG•2-PG and binary
BPGM•2-PG complex showed a significant conformational change upon ligand binding. The sidechain of Glu13 swings outward away from the active site, making contacts with Glu33 and Lys18
at the surface of the protein (Figure 36A and B), in contrast to the unliganded BPGM, where the
side-chain of Glu13 is directed toward the active site making several water- mediated interactions
with Arg10, His11, Glu89 and Gly189. These conformational changes are important to
accommodate the binding of the substrate and to expose the phosphorylation site at the bottom of
the active site for catalysis.
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Figure 36. (A) Superposition of the important residues in the active site of monomer A of the
ternary BPGM•3-PGA•2-PG complex (cyan) and unliganded BPGM (PDB ID 3NFY; gray)
structures. (B) Superposition of the important residues in the active site of monomer A of the
binary BPGM•2-PG complex (cyan) and unliganded BPGM (gray) structures.

Another significant difference was observed in the main-chain residues from Arg99
toThr122 located at the entrance of monomer A active site. These amino acids were observed to
move toward the active site placing the side-chains of Arg100, Arg116, and Arg117 into the active
site (Figure 36A and B). The conformation of Arg117 is stabilized by hydrogen-bond interactions
between the side-chain of Arg117 and Thr211. Moreover, Arg113 showed a large movement to
make interactions with Asn209. Also, the C-terminal residues beyond Gly236 stretch forward and
close the active pocket, thus maintaining the active site in the catalytically closed conformation.
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These interactions were missing in the unliganded structure, making the unliganded structure
appear to be in an open catalytically inactive conformation.
Structural comparison of the active site of monomer B of the ternary BPGM•2,3-BPG•2PG or binary BPGM•2-PG complexes with the unliganded structure (PDB ID 3NFY) showed
conformational changes of the residues at the bottom of the active site from His11 to Ser24 in a
similar fashion as described for monomer A in which the side-chain of Glu13 has significant
movement, exposing the phosphorylation site at the bottom of the active for catalysis (Figure 37A
and B). However, unlike monomer A, but similar to the unliganded structure, the residues at the
entrance of the active site, Arg100, Arg116, and Arg117, were highly disordered making it difficult
to determine their side-chain direction and interactions. Furthermore, the hydrogen-bond
interaction between the Arg113 with Asn209 observed in monomer A of the ternary BPGM•3PGA•2-PG and binary BPGM•2-PG complex structures was absent in monomer B. In addition,
the C-terminus residues beyond Ile-240 in monomer B of the ternary BPGM•2,3-BPG•2-PG and
beyond Ile-245 in the binary BPGM•2-PG were missing. It should be noted that the C-terminus of
the unliganded structure was resolved up to Asp250. The observed significant disorder of the
residues at the entrance of the active site and at the C-terminus made the active site of monomer
B appear to be in an open conformation resembling the catalytically inactive open active site of
the unliganded structure. The open active site conformation of monomer B therefore reflects weak
binding of 2-PG to monomer B active site in contrast to the high affinity binding of 2-PG to the
active site of monomer A.
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Figure 37. (A) Superposition of the important residues in the active site in monomer B of
the ternary BPGM•3-PGA•2-PG complex (violet) and unliganded BPGM (PDB ID 3NFY;
yellow). (B) Superposition of the important residues in the active site in monomer B of the binary
BPGM•2-PG complex (violet) with the unliganded BPGM structure (yellow).

In summary, the inequivalence in the conformational behavior of the active sites of both
monomers suggests the existence of sequential interaction or allostery across the BPGM subunits
that is likely induced by the binding of 2-PG at the dimer interface, thereby affecting the binding
affinity of a substrate at the second subunit active site. Therefore, we propose that binding of a
ligand at the dimer interface will affect the utilization of 3-PGA or 2,3-BPG as a substrate and
induce negative cooperativity in which it lowers the binding affinity of the ligand in the active site
of the second monomer, making only one site catalytically reactive.
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4.2.3.

Citrate complex with BPGM

Interestingly, co-crystallization of citrate with BPGM only resulted in citrate binding to
monomer A is active site and not that of monomer B. Nonetheless, like the ternary BPGM•2PGA•2-PG and binary BPGM•2-PG complexes, the binary BPGM•citrate also showed bound
citrate at the dimer interface. In this structure, monomer A showed well defined Arg100 and
Arg116 density at the entrance of the active site, while the side-chain of Arg117 showed disorder
(similar to the unliganded BPGM active site), making monomer A active site appears to be in a
partially closed conformation (Figure 38). The active site of monomer B of the binary
BPGM•citrate, however, demonstrated significant disorder with Arg100, Arg116 and Arg117
having no electron density. Furthermore, the binary BPGM•citrate complex showed disorder in
both monomers, lacking electron density beyond Gly236.
From the forgoing, it appears that the binding affinity of citrate to the active site is weaker
than 3-PGA or 2-PG as reflected in the partially closed structure at monomer A, and apparent is
missing any bound molecule at monomer B. The binary BPGM•citrate structure with one ligand
bound per dimer best fits an extreme form of negative cooperativity named “half of sites reactivity”
kinetic model, in which the binding of the ligand to the dimer interface inhibits the binding of the
ligand in the active site of the second monomer.204 We assume that the strength of the negative
cooperativity depends on the structure and the strength of the interactions of the ligand at the dimer
interface. Since the citrate is larger than the 2-PG structure and exhibits more interactions at the
dimer interface, the negative cooperativity was observed to be more significant.
In conclusion, it seems that the best working hypothesis at the moment is that binding of
ligand at the dimer interface induces a negative cooperativity behavior, decreasing the affinity or
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completely inhibiting the binding of ligand at the active site of the second monomer. This is the
first such report that displays such an allosterism in BPGM.

Figure 38. Superposition of the important residues in the active site in monomer B of the binary
BPGM•citrate complex (cyan) and the unliganded structure of BPGM (PDB ID 3NFY; gray).

4.2.4.

Computational solvent mapping of BPGM using FTMap

The identification of non-catalytic or allosteric binding site at the dimer interface
encouraged us to search for other potential allosteric sites on BPGM surface and evaluate the target
druggability. Therefore, we carried out computational solvent mapping analysis of the BPGM
surface using the FTMap server as described above (4.1.2). Therefore, we will be screening the
site against virtual drugs library to find potential allosteric modulators to be used for SCD
therapeutics, as described in chapter 5.
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CHAPTER 5

5. SPECIFIC AIM 3: Identify BPGM synthase inhibitors and/or phosphatase activators
that can be used as leads for SCD drug discovery

Targeting the BPGM enzyme by inhibiting the synthase and/or activating the phosphatase
activity to reduce 2,3-Bisphosphoglycerate (2,3-BPG) levels in sickle RBC is an interesting
therapeutic approach for sickle cell disease (SCD). Up to date, no drug screening study is reported
in the literature to identify small molecules against BPGM for therapeutic purposes. One of the
objectives of this chapter is to identify novel lead BPGM modulators that can be developed further
in the future as drug candidates for the treatment of SCD. To reach our objective, we have utilized
different in- silico techniques to search for BPGM modulators against the active site and the noncatalytic binding site at the dimer interface of the protein. The resulted active site hits were
obtained and tested for their effect on BPGM phosphatase and synthase activities.

5.1. Specific Aim 3A: Identification of BPGM modulators against the active site
5.1.1.

Pharmacophore- based virtual screening and molecular docking

In this study, an in silico method that involves a combination of a ligand-based virtual
screening and a structure-based molecular docking was implemented to identify putative BPGM
modulators targeting the active site. The ligand-based virtual screening exercise is based on the
generation of a three-dimensional (3D) pharmacophore model from a reference ligand. The
pharmacophore model empirically defines the molecular features of the reference ligand that are
critical for its interaction with the enzyme active site. This model was used as a template to search
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for compounds that match the selected pharmacophoric features in the virtual chemical
database.205–207
X-ray crystal structure of BPGM in complex with 3-PGA was retrieved from the protein
data bank (PDB ID 2H4X) and 3D pharmacophore queries were generated from the interaction of
3-PGA with BPGM at the active site using the UNITY database searching program in the
molecular modeling software (SYBYL-X 2.0, Tripos Inc.).205 Figure 39 represents the constructed
3D pharmacophore queries from 3-PGA, which include: (1) a negative center placed at the position
of the phosphoryl group of 3-PGA, (2) an acceptor atom at the position of the carboxylate group
of 3-PGA, and (3) a donor atom at the hydroxyl group of 3-PGA. The negative center searches for
a negatively-charged group from the database, such as a carboxylate, sulfate, or phosphate. The
acceptor and donor atoms denote sites for an atom that can act as a hydrogen-bond acceptor and
hydrogen-bond donor, respectively. A receptor site constraint within 5 Å of the ligand was applied.
Consequently, the pharmacophore model was screened using a flexible directed tweak algorithm
via a 3D flexible database search (UNITY, Tripos Inc.)205 against diverse set of ligands retrieved
from the Molport virtual chemical library, (www.molport.com), which is a public access database
that contains over 7 million commercially available compounds, to identify positive hits that match
the requirements of the queries.

’
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Figure 39. The 3D queries on 3-phosphoglycerate.
The initial UNITY search resulted in 25,000 hits, and the results were viewed using the
hitlist manager in SYBYL-X 2.0 software. The hit lists were filtered down to 12,000 by removing
duplicates, and linear chain compounds. Also, the hit lists were filtered down by applying the
Lipinski's ‘Rule of Five’ to remove compounds that are unlikely to be good drug candidates. The
Lipinski's ‘Rule of Five’ suggested that five keys physiochemical parameters must exist in drugs
to make them orally bioavailable, which include compounds with molecular weight of less than
500 Dalton; the lipophilicity of the compounds as represented by (clogP) have to be less than five;
compounds have to contain less than five hydrogen-bond donating groups, and less than 10
hydrogen-bond accepting group.208 All parameters were applied except for the molecular weight,
where a 350 Dalton cutoff was used instead. Next, the virtual screening hits, i.e., molecules that
met the pharmacophore queries requirements were selected and docked against the BPGM active
site using the GOLD 5.4. docking program. Gold is an automated ligand docking software that
employs a genetic optimization algorithm to predict different binding poses and conformations of
the ligand with the target protein.209,210 The program assigns scores of the different binding poses
by using a built-in fitness function, which is a metric for measuring the binding of ligand to protein,
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and ranks the ligands based on the binding score. The higher the scoring value, the better the
docking result. The scoring function used in this exercise was the ChemPLP score, which is the
default scoring function in GOLD that takes into account the contribution of hydrogen-bonds, van
der Waals, and repulsive interactions between the protein target and heavy atoms of the ligand.
Following, the top-ranking list that has the compounds with the highest function score were sorted
based on their ligand efficiency (LE) score. The LE was used as an extra metric to estimate the
efficiency of the ligand by measuring the average binding affinity per an atom of a ligand to the
active site of the target protein. It is mathematically calculated by dividing the free energy of
a ligand (ΔG) by the number of non-hydrogen heavy atoms (HA) in the molecule.211,212
LE = ∆G/ [number of HA]
Among the top 10 compounds selected, 6 compounds were purchased for
experimental activity assay. The chemical structures of the top scoring compounds are shown in
Figure 40.

Figure 40. Top hits identified from the virtual screening for the active site.
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5.1.2.

Machine-learning based virtual screening by Atomwise

Atomwise is a pharmaceutical company that uses an AtomNet™ technology for
rational drug design.213 AtomNet technology is a convolutional deep learning neural network
employed to conduct a machine learning-based virtual screening exercise to find potential lead
compounds from a vast database of chemical compounds against any biological target.213 Dr. Safo’s
research group was granted the opportunity to screen the BPGM target using their artificial
intelligence virtual screen as a part of their AIMS program. The AIMS screening yielded 72 small
molecules for experimental testing.

5.1.3.

PGM1-004A

PGM1-004A (Figure 41), is an anthraquinone derivative compound found by
Hitosugi group in an effort to identify anticancer therapies targeting the Warburg effect (aerobic
glycolysis), a known cancer hallmark, through inhibiting the phosphoglycerate mutase 1 (PGAM1)
activity.214 PGAM1 is a glycolytic enzyme that catalyzes the reversible isomerization of 3-PGA
into 2-phosphoglycerate (2-PGA) with an intermediate product formation of 2,3-BPG. PGAM1
shares 50% sequence identity and conserved residues at the active site with BPGM. 157 Also, both
enzymes catalyze the same three catalytic reactions; the synthase, phosphatase, and mutase
activities; but with different rates. PGM1-004A inhibits PGAM1 enzyme with an IC50 of 13 μM.214
We hypothesize that the binding of PGM1-004A to BPGM will result in pharmacological
inhibition similar to the one obtained from their effect on PGAM1. Therefore, PGM1-004A was
purchased from (MedChemExpress LLC) to evaluate its activity against BPGM.
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Figure 41. Chemical structure of PGMI-004A.

5.2. Specific Aim 3B: Identification of BPGM allosteric modulators
5.2.1.

Molecular docking against BPGM dimer interface

As reported in chapter 4, the X-ray crystallographic studies of BPGM in complex with 2PG and citrate revealed a novel binding site at the dimer interface. Furthermore, based on the
FTMap analysis, the dimer interface was predicted to be a druggable target. On this basis, a
molecular docking experiment was carried out by our collaborator, Dr. Abdelsattar Omar, from
King Abdulaziz University in Saudi Arabia to identify potential allosteric modifiers targeting the
dimer interface. Therefore, a library of approved drugs was docked against the dimer interface site
using our determined crystal structure of BPGM in complex with 2-PG. The molecular docking
study was performed using the Glide docking software 12.3 (Schrödinger, New York, NY).215,216
The docking calculation was performed with Glide in the default standard-precision (SP) mode,
using GlideScore for ligand ranking. The top 10 hits (Figure 42) were selected for further analysis
using molecular dynamic simulation.
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Figure 42. Top hits identified from the molecular docking for the allosteric site.

5.2.2.

Molecular dynamic simulation of the top scoring docked compounds

with BPGM
The binding of the top scored compounds from the molecular docking exercise were further
validated using Desmond Molecular dynamic simulation (Schrödinger, New York, NY)217 to
confirm their binding stability with BPGM. This work was also done by Dr. Abdelsattar Omar
from King Abdulaziz University in Saudi Arabia.
The results of the top-ranking compounds, Methyldopa, Baclofen, Carbamazepine,
Mesalazine, Memantine, and Hydrochlorothiazide from the molecular dynamic simulation (Figure
43) showed that the protein-ligand root-mean-squared deviation (RMSD) of each compound is
stable throughout the trajectory (50 ns). The results obtained from the simulation suggest the ability
of each compound to form a stable complex at the dimer interface site.
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Figure 43. Protein-ligand RMSD graphs for the top-ranking compounds from the molecular
dynamic simulation.

5.3. Specific Aim 3C: Examination of the modulators effect of BPGM phosphatase
and synthase activities

The compounds obtained from the in-house virtual screening and molecular docking
exercise, Atomwise’s molecular screening, and PGMI-004A were tested for their in vitro effect on
BPGM phosphatase and synthase activities. The compounds were first screened for their effect on
the phosphatase activity using the malachite green assay, which is a colorimetric assay for
measuring Pi liberated from 2,3-BPG hydrolysis reaction. The cutoff level selected for the
screening assay was 50% modulation of the phosphatase activity. The compounds showing ±50%
phosphatase inhibition and/or activation were selected for dose-response analysis. Also, selected
compounds were tested further for their effect on BPGM phosphatase activity using the
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PGK•GAPDH•BPGM phosphatase coupled assay, and for their effect on BPGM synthase activity
using GAPDH.BPGM synthase coupled synthase assay.

5.3.1.

Compound screening using malachite green assay

A total of 78 compounds, including 6 compounds from the in-house virtual screening and
molecular docking exercise, and 72 compounds from Atomwise’s screening were screened initially
for their effect on BPGM phosphatase activity using the malachite green phosphate assay kit
(Sigma Aldrich, MAK307-1KT). Malachite green assay is a colorimetric assay used to measure Pi
released during 2,3-BPG hydrolysis reaction. The liberated Pi in the reaction mixture form a
complex with molybdate in the malachite green reagent turning the color of the reaction mixture
to green that is detectable at A620 nm using BMG LABTECH CLARIOstar® Plus microplate
reader. The assay was carried out with a final assay volume of 100 μL in a clear flat-bottom 96well plate. First, a final concentration of 100 µM compounds in 1% dimethyl sulfoxide (DMSO)
(v/v) was added to the empty wells. Then, 100 μM 2,3-BPG (~Km of 2,3-BPG) in buffer containing
20 mM Tris-HCl and 100 mM NaCl (pH 7.5) was added to each well. The reaction was initiated
by the addition of 5 μM BPGM and allowed to react for 50 min at 37°C. A control (i.e., DMSO),
a positive control using 2-phosphoglycolate (2-PG) as an activator and 3-PGA as an inhibitor were
included in each experiment. Next, an aliquot from the reaction mixture was diluted 8 times with
the assay buffer. The reaction was stopped by the addition of the malachite green dye. Following,
the mixture was incubated at room temperature for 30 min for color development, and the
absorbance was measured at A620 nm. The concentrations of Pi were determined with a Pi standard
curve, and the effect of the compounds on the initial velocity of the phosphatase reaction was
measured as mole of Pi/min. During the study, we observed that a number of the compounds
102

showed poor solubility and aggregation in the assay mixture. Therefore, the malachite green dye
was supplemented with 0.01% Triton X-100 to reduce the aggregation. In addition, the malachite
green dye was observed to slowly form precipitations over the 30 min incubation time, which we
resolved by diluting the reaction mixture with the buffer before the addition of the reagent for
detection.
None of the compounds (Compounds 1, 2, 3, 4, 5, 6) obtained from the in-house virtual
screening and molecular docking exercise showed any effect on the phosphatase activity (Figure
44). The compounds obtained from Atomwise’s molecular screen demonstrated modulation of the
BPGM phosphatase activity, including activation or inhibition (Figure 45-48). The results showed
that compounds B11, E7, F2, and F12 exhibited more than 50% activation, while compounds A10,
B6, C7, C8, and D2 showed more than 50% inhibition. Therefore, these compounds were picked
for validation using dose-response analysis. Unfortunately, none of the compounds showed dose
dependent modulation of the BPGM phosphatase activity. The precipitation of the malachite green
dye due to over saturation or the precipitation of the protein in the acidic assay condition may
explain the likely false positive hits and/or the inability to observe dose-response effect. The
malachite green assay needs to be further optimized to get accurate screening results.
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Figure 44. The effect of compounds 1-6, 2-PG, and 3-PGA on BPGM phosphatase activity
using malachite green assay.
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Figure 45. The effect of compounds A4-B9 on BPGM phosphatase activity using malachite
green assay.
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Figure 46. The effect of compounds B10-D5 on BPGM phosphatase activity using malachite
green assay.
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Figure 47. The effect of compounds D6-E12 on BPGM phosphatase activity using malachite green
assay.
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Figure 48. The effect of compounds F1-B11, 2-PG, and 3-PGA on BPGM phosphatase activity
using malachite green assay.
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5.3.2.

Compound screening using PGK•GAPDH•BPGM phosphatase

coupled assay
Above, even though we observed significant modulation of BPGM with several
compounds from Atomwise, none of them showed dose-response effect using the malachite assay.
We decided to use an alternate BPGM phosphatase assay, the PGK•GAPDH•BPGM coupled
phosphatase assay, to study the dose-response effect of selected Atomwise’s compounds, including
A5, A10, B6, C7, C8, E7 and F2. The PGK•GAPDH•BPGM phosphatase coupled assay indirectly
measures the effect of the compounds on BPGM phosphatase activity by coupling BPGM
phosphatase activity with the activity of Phosphoglycerate kinase (PGK) and Glyceraldehyde-3phosphate dehydrogenase (GAPDH) enzymes. In this assay, BPGM hydrolyzes 2,3-BPG to 3PGA and Pi. PGK converts 3-PGA to 1,3-BPG, which is a substrate for GAPDH. In the presence
of NADH, GAPDH converts 1,3-BPG and NADH to glyceraldehyde-3-phosphate (GAP) and
NAD, respectively. The oxidation of NADH to NAD, which correlates with 2,3-BPG hydrolysis
activity, is detected spectrophotometrically at A340 nm.
The assay was carried out with a final volume of 200 µL in a clear flat-bottom 96-well
plate. The assay reaction contained a final concentration of 100 µM compound in 1% DMSO (v/v),
50 mM Tris-HC1 buffer at (pH 7.5), 10 mM MgCl2, 0.2 mM NADH, 3 mM ATP, 3.3 U/ml
GAPDH, 2.3 U/mL PGK, and 5 µM BGPM. The reaction was initiated by the addition of 400 µM
2,3-BPG, and monitored for 20 min at A340 nm using a BMG LABTECH CLARIOstar® Plus
microplate reader. A DMSO control, a positive control with 2-PG as an activator, and a negative
control (lacking 2,3-BPG) were included in each experiment. The compounds showed no effect
on the phosphatase activity (Figure 49). The PGMI-004A compound was also tested with the
PGK•GAPDH•BPGM phosphatase coupled assay, and the results did not show any significant
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modulation of the phosphatase activity. It is clear that the results from the coupled assay are not
consistent with the malachite green assay. The inconsistent results are related to the limitations in
both assays. The malachite green assay needs to be optimized further to reduce the precipitation
that affects the reading output. The PGK•GAPDH•BPGM coupled assay exhibits low sensitivity,
requiring high substrate concentration for the activity to be detected.

Figure 49. The effect of compounds A5, A10, B6, C7, C8, E7, and F2 on BPGM
phosphatase activity using PGK•GAPDH•BPGM phosphatase coupled assay.
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5.3.3.

Compound screening with GAPDH.BPGM coupled Synthase Assay

The compounds were also tested for their effect on BPGM synthase activity using the
GAPDH•BPGM synthase coupled assay, which is a spectrophotometric assay that indirectly
measures 2,3-BPG synthesis by coupling BPGM synthase with GAPDH activity. GAPDH is used
to convert GAP and NAD into 1,3-BPG and NADH, respectively. The reduction of NAD to
NADH, which correlates with 2,3-BPG formation, was monitored at A340 nm using BMG
LABTECH CLARIOstar® Plus microplate reader.
The compounds obtained from the in-house virtual screening and the molecular docking
exercise (Compounds 1-6) were tested for their effect on the BPGM synthase activity, and the
results did not show any significant effect. In addition, selected Atomwise compounds (A5, A10,
B6, C7, and C8) were analyzed and the results also showed no effect on the synthase activity
(Figure 50). Interestingly, PGM1-004A, the known inhibitor of PGAM1, showed a significant
inhibitory effect on the synthase activity in a dose-dependent manner. A dose response experiment
using 2-fold serial dilutions of the PGMI-004A (1.5 to 200 µM) showed that PGM1-004A inhibits
BPGM synthase activity with an IC50 value (50% inhibitory concentration) of 50±11 µM. This
compares with IC50 of 13.1 μM with PGMI-004A inhibition of PGAM1. The data was plotted
using nonlinear regression to fit the % inhibition vs. log µM compound concentration (Graphpad
Prism software) (Figure 51). The fact that PGMI-004A showed a clear inhibitory data with the
synthase activity suggest that the assay works and the other compounds likely do not affect the
synthase activity.
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Figure 50. The effect of compounds A5, A10, B6, C7, and C8 on BPGM synthase activity using
GAPDH•BPGM synthase coupled assay.
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Figure 51. Dose-response curve of PGMI-004A on BPGM synthase activity .
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5.4. Specific Aim 3D: Elucidate the X-ray crystallographic binding between BPGM
and PGMI-004A.

PGMI-004A was the only compound that appeared to inhibit BPGM synthase activity.
Therefore, several attempts were made to co-crystalize PGMI-004A with BPGM to elucidate its
atomic interaction with the enzyme. We believe that the binding interactions of PGMI-004A with
BPGM would provide useful insight into the design of selective BPGM synthase inhibitors.
Several attempts of co-crystalizing PGMI-004A with BPGM resulted in crystals that either
did not diffract or were low-resolution. However, in a last attempt, a cubic crystal form was
obtained, and diffraction data collected to 2.3 Å. The structure was determined by Phaser-MR
(simple interface) molecular replacement with the Phenix software package195 using the
monomeric unliganded structure of BPGM (PDB ID 3NFY) as a search model. The dimeric
structure underwent iterative cycles of refinement with Phenix along with manual refinement and
model building using COOT.195–197 Crystallographic and refinement parameters are summarized
in (Table 8).
The co-crystallized structure of BPGM with PGMI-004A showed no apparent bound ligand
in the active site of both monomers nor anywhere in the structure (Figure 52). Both monomers
were modelled into density from Ser2 to Leu235. The last 21 residues in the C-terminus were
disordered and therefore could not be modelled. The significant disorder in the C-terminus along
with the disordered side-chain of Arg117 resulted in both active sites being in open conformation,
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similar to the open conformation of the previously reported unliganded BPGM structure (PDB ID
3NFY)

Figure 52. Overall structure of BPGM in complex with PGMI-004.
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Table 8. Crystallization and refinement parameters of BPGM•PGMI-004A complex.
Data set
Data collection
Resolution (Å)
Space group
Unit cell dimensions
[a, b, c (Å)]
Total no. of reflections
Completeness
Refinement
Rwork
Rfree3a

BPGM•PGMI-004A

2.3 Å
P212121
52.13

78.8

120.87

22661
99.32
0.30
0.38

Molprobity statistics

a

All atom clash score

11.63

Ramachandran plot (%)
Favored
Allowed
Outliers

93.75
5.17
1.08

Rotamer outlier

0.95

Wilson B factor

25.97

Rfree was calculated from 5% randomly selected reflection for cross-validation. All other measured

reflections were used during refinement
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5.5. Discussion

Targeting the central enzyme of the Rapoport Leubering pathway, BPGM, is suggested as
a potential therapeutic opportunity for SCD drug discovery. The fact that BPGM is exclusively
expressed in erythrocyte, and is the only enzyme responsible for the synthesis and hydrolysis of
2,3-BPG makes it an attractive target to explore.
We have utilized different techniques to search for BPGM modulators. First, an in-house
pharmacophore-based virtual screening and molecular docking against BPGM active site were
performed, which yielded 6 virtual hits that were purchased for experimental testing. Also, a
computational machine learning-based virtual screening against BPGM active site has been
performed by the pharmaceutical company, Atomwise, as part of their artificial intelligence
molecular screen (AIMS) program and resulted in 72 compounds. Lastly, a well validated inhibitor
of PGAM1, named PGM1-004A, were purchased for experimental testing.
In addition to targeting BPGM active site, molecular docking was performed against the
new non catalytic/allosteric sites at the dimer interface to identify potential allosteric modulators
of BPGM activity. This novel binding site was identified during the conduct of this project.
Following, the binding of the top scoring docked compounds was confirmed by analyzing their
binding stability with BPGM using molecular dynamic simulation. The top 6 compounds from the
molecular

dynamic

simulation,

Methyldopa,

Baclofen,

Carbamazepine,

Mesalazine,

Hydrochlorothiazide, and Memantine, have been purchased for experimental testing.
Thus, a total of 79 compounds targeting the active site of BPGM were tested for their effect
on BPGM phosphatase and synthase activities. Initially, the compounds were screened using the
colorimetric malachite green assay. This assay was utilized as direct, robust and alternative assay
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to

the

existing

hazardous

radioactive

assay

or

the

BPGM

continuous

coupled

assay.152,154,166,167,170,179
Screening with the malachite green assay, however, exhibited several challenges as the hits
could not be validated with dose-response analysis. The false positive is likely due to malachite
green dye precipitation or protein/compounds aggregation at the acidic assay condition during the
incubation period (30 min), affecting the stability of the end-point signal.
The compounds were also tested for their effect on the phosphatase activity using the
PGK•GAPDH•BPGM phosphatase coupled assay. Likewise, none of the compounds showed any
modulation in the phosphatase activity. The PGK•GAPDH•BPGM coupled assay also has several
limitations, including less sensitivity when compared to the malachite green assay. For the BPGM
phosphatase activity to be detected with this assay, the substrate and the enzyme need to be in high
concentration. The substrate (2,3-BPG) concentration is 400 µM, which is four times the Km value
of 2,3-BPG (~100 µM), significantly higher than the substrate used in the malachite green assay
(100 µM, similar to 2,3-BPG Km). The high substrate concentration could result in overcoming the
modulation exerted by any potential inhibitors and/or activators. It is worth mentioning that this
assay has always been used with the activator, 2-PG.
The compounds were also tested for their effect on the BPGM synthase activity using the
GAPDH•BPGM synthase coupled assay. Similarly, none of the compounds showed any effect on
the synthase activity with the exception of PGMI-004A. PGMI-004A showed inhibition in a dosedependent manner, with an IC50 of 50±11μM. The inability of PGMI-004A compound to show any
modulation

of

the

phosphatase

activity

confirms

either

the

low

sensitivity

of

PGK•GAPDH•BPGM phosphatase coupled assay or that PGMI-004A preferentially modulates
the synthase activity. The dissociation equilibrium constant of the enzyme-inhibitor complex (Ki)
115

could not be obtained due to the inability to vary the 1,3-BPG concentration in the coupled
synthase assay as 1,3-BPG is commercially unavailable and has to be enzymatically synthesized
in situ during the assay.
The co-crystallization of BPGM with PGMI-004A resulted in a structure with a resolution
of 2.3 Å. However, the co-crystal structure did not show bound PGMI-004A at the active site or
any other sites. Also, a significant disorder was observed at the C-terminus. Due to the unliganded
active site, both active sites expectedly are in open conformations (Figure 53). The crystallization
condition needs to be optimized to obtain BPGM•PGMI-004A complex structure.
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Figure 53. (A) Superposition of the BPGM•PGMI-004A dimer (lime green) with the unliganded
BPGM dimer (PDB ID 3NFY, light purple). (B) Superposition of the active site residues of
monomer A of BPGM•PGMI-004A and the unliganded BPGM structures.
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CHAPTER 6

6. SUMMARY AND CONCLUSION

Bisphosphoglycerate mutase (BPGM) is a multifunctional enzyme in the RapoportLuebering pathway, a glycolytic bypass predominantly presents in red blood cells (RBCs),
responsible for the synthesis and hydrolysis of 2,3-Bisphosphoglycerate (2,3-BPG).5,7–9 The
synthesis of 2,3-BPG is the main activity of the enzyme (synthase activity), while the hydrolysis
of 2,3-BPG (phosphatase activity) is physiologically low but can be potently activated by 2phosphoglycolate (2-PG) through a poorly understood mechanism.7–9 2,3-BPG is crucial for RBCs
oxygen delivery by binding directly to hemoglobin (Hb); stabilizing the deoxygenated Hb
conformation, and facilitating the release of oxygen to tissues.12–14 The level of 2,3-BPG increases
as an adaptation mechanism in clinical conditions where the oxygen transport is compromised. In
sickle cell disease (SCD), 2,3-BPG level is abnormally elevated due to glycolytic activation in
response to hypoxia, which significantly contributes to the disease pathophysiology. The elevated
2,3-BPG directly promotes hypoxia-induced sickle Hb (HbS) polymerization and subsequent
RBCs sickling.22,150,17
Modulating BPGM activity through inhibiting the synthase activity or activating the
phosphatase activity to reduce 2,3-BPG levesl is considered an attractive approach to target HbS
polymerization and RBC sickling. The activation of the phosphatase activity by 2-PG has been
shown to reduce 2,3-BPG level and consequently reduce HbS polymerization and RBCs
sickling.150
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Therefore, the specific aims of this project were to: (1) Elucidate the steady state kinetics
of BPGM synthase and phosphatase activities and optimize the activity assays to be used for
compounds screening, (2) Elucidate the atomic interactions of BPGM phosphatase with its
effectors, and identify allosteric binding site(s) of BPGM, (3) Identify BPGM synthase inhibitor
and/or phosphatase activators that can be used as leads for SCD drug discovery.
In this dissertation, we have in chapter 3 studied the steady-state kinetics of BPGM
synthase and phosphatase activities in order to optimize and validate appropriate enzymatic assays
for compound screening. BPGM synthase activity was studied using GAPDH•BPGM synthase
coupled assay. Due to the complexity and the limitations of this assay, it was not possible to obtain
detailed steady-state kinetic parameters of BPGM synthase activity. However, the assay was used
for compound screening in a low-throughput setting. BPGM phosphatase activity, on the other
hand, was studied using the colorimetric malachite green assay, and PGK•GAPDH•BPGM
phosphatase coupled assay. The steady-state kinetic parameters of the phosphatase activity were
characterized with both assays and the conditions of the assays were optimized for the compounds
screening experiments. The malachite green assay was utilized as a robust assay that can be easily
adapted to high-throughput setting.
Next, we shed the light on 2-PG activation mechanism of BPGM phosphatase activity by
studying the kinetic of 2-PG activation using PGK•GAPDH•BPGM phosphatase coupled assay,
and structurally elucidated the binding mode of BPGM with 2-PG using X-ray crystallography in
chapter 4. The kinetic analysis showed 2-PG activation mechanism to be mixed of noncompetitive
and competitive mechanism suggesting the binding of 2-PG to the active site as well as a noncatalytic or allosteric site. The structural analysis of BPGM in complex with 2-PG, in presence and
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absence of 2,3-BPG, confirmed the kinetic finding as it revealed for the first time a novel noncatalytic or allosteric binding site for 2-PG at the dimer interface in addition to its predicted or
known active site binding. Moreover, we have elucidated the binding mode of citrate, a known
BPGM phosphatase inhibitor, to gain further understanding of the phosphatase molecular
mechanism. The co-crystal structure of BPGM in complex with citrate showed citrate bound to
one active site per dimer as well as at the dimer interface. On this basis, we proposed the existence
of negative cooperativity induced by 2-PG or citrate binding at the dimer interface.
Furthermore, in chapter 4, we have also carried out a computational solvent mapping
technique using FTMap online server in an attempt to identify additional BPGM binding sites,
including allosteric site, and predict their druggability. The results demonstrated the dimer
interface site as the most important and likely druggable site of BPGM, supporting our
crystallographic findings of the dimer interface as a potential druggable target.
In chapter 5, multiple in-silico approaches aimed to identify BPGM modulators against the
active site were conducted to find potential modulators for BPGM activity. The results from the
compounds screening did not show any potential BPGM modulatory effect except for PGMI-004A
that inhibited BPGM synthase activity (IC50 of 50±11μM). PGMI-004A is an already well
validated inhibitor for the homologous enzyme PGAM1.214 Based on the inhibitory effect of
PGMI-004A, the anthraquinone chemical scaffold can be used to develop specific inhibitors for
BPGM synthase activity. The crystal structure of BPGM in complex with PGMI-004A did not
show any ligand bound to BPGM, and further optimization of the crystallization condition is
required to obtain the bound BPGM•PGMI-004A complex.
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Apart from targeting the active site of BPGM, the novel dimer interface was also docked
against a library of approved drugs, and the top scoring compounds were analyzed for their binding
stability with BPGM. Six of the top ranked compounds were obtained for experimental testing.
The identification of the allosteric site at the dimer interface opens new promising avenue
in the development of allosteric modulators for BPGM given the challenges in targeting BPGM
active site, owing to its highly charged environment. In addition, the saturation of the intracellular
substrate may overcome the effects of any potential competitive modulators.
In conclusion, this dissertation provides novel insights into the mechanism of 2-PG
activation and citrate inhibition of BPGM phosphatase activity. In addition, it explored a novel
therapeutic approach to SCD by targeting the reduction of 2,3-BPG concentration that can mitigate
hypoxia-induced HbS polymerization and RBC sickling.
The limitation of this project is the challenges experienced with the available BPGM
activity biochemical assays that limited their use for high-throughput screening. Therefore,
developing direct and sensitive assays is needed to allow for discovery of potential BPGM
modulators.
Future research should also consider experimental and computational efforts to expand our
understanding of BPGM as a molecular target and its catalytic mechanisms. For instance,
understanding the role of the C-terminus in the transition of active to inactive conformation and
the relationship between the binding at the dimer interface and BPGM dimerization by using
molecular dynamic simulation techniques or site directed mutagenesis at the dimer interface site.
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CHAPTER 7

7.

EXPERIMENTAL SECTION

General information: Unless stated otherwise, all reagents used in the biochemical assays
were purchased from Sigma-Aldrich (St. Louis, MO) and Thermo Fisher Scientific (Waltham,
MA).

7.1. BPGM expression and purification:

Human BPGM clone in pET-30b (+) vector was purchased from (GenScript USA Inc.) and
transformed into E.coli BL21-CodonPlus (DE3)-RIPL cells for expression. The transformed cells
were streaked in a kanamycin plate and incubated overnight at 37º C. A single colony was picked
from the kanamycin plate and grown overnight with shaking at 37º C in Luria-Bertani (LB) broth
containing 100 µg/mL kanamycin. The culture was then inoculated (1:20) into 6 L of LB media
and grown at 37º C under aerobic conditions until the optical density at 600 nm (OD600) reached
0.6. Next, the cell culture was induced with 0.2 mM isopropyl-thio-β-D-galactosidase (IPTG) and
further incubated at lower temperature of 30º C for 8 h. Cells were harvested by centrifugation and
cell pellets were resuspended in a buffer containing 50 mM Tris-HCl, 10 mM imidazole and 300
mM NaCl at pH 8 (Buffer A). The resuspended cells were lysed using Avestin Emulsiflex
(Emulsiflex C-3, operating at > 20,000 PSI), followed by high-speed centrifugation at 12,000 rpm
for 20 min. The supernatant was filtered and loaded onto a 5-ml HisTrap HP column (GE
Healthcare Bio-Sciences) pre-equilibrated with buffer A. The purification process was carried out
using ÄKTA fast protein liquid chromatography (FPLC).
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First, the column was washed with buffer A that contain low concentration of imidazole
(10 mM) to reduce the non-specific binding proteins. Then, the imidazole gradient was gradually
increased using a buffer containing 50 mM Tris-HCl, 250 mM imidazole and 300 mM NaCl at pH
8 (buffer B) to remove the non-specific binding proteins until the protein was eluted with 75 mM
imidazole concentration. Protein fractions were collected and the purity was assessed by single
band on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 54). The
pure fractions were then pooled and dialyzed overnight at 4 ºC using buffer containing 20 mM
Tris-HCl and 150 mM NaCl at pH 7.5. The dialysis buffer was then exchanged to a second dialysis
buffer containing lower salt concentration of 20 mM Tris HCL and 100 mM NaCl (pH 7.5) for 4
h. The protein concentration was determined spectrophotometrically using BPGM extinction
coefficient A280 1.63 AU = 1 mg/mL.

Figure 54. SDS-PAGE analysis of BPGM expressed in E.coli (1) E.coli crude extract (2)
Purified BPGM fractions (3) Molecular weight standards.

123

7.2. BPGM synthase activity:

BPGM synthase activity was measured using a continuous spectrophotometric coupled
enzymatic assay developed by Garel et al.179 with some modifications, using an Agilent 8453 UVVIS spectrophotometer. The assay was performed in a total volume of 1 mL mixture containing
50 mM Tris HCl, 7 mM monobasic potassium phosphate (KH2PO4) at pH 8, 2U/mL
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 1 mM Nicotine diamine dinucleotide
(NAD), 2.9 mM Glyceraldehyde-3-phosphate (GAP), and 40 µM 3-phosphoglycerate (3-PGA) in
the presence and absence of 1mM 2-phosphoglycolate (2-PG). The reaction was initiated by the
addition of various concentrations of BPGM (0.1-2.5 µM), and monitored by the increase in A340
nm that corresponds to the reduction of NAD for 10 min. The activity was obtained by calculating
the initial velocity (Δ A340 nm/min) from the slope of the tangent line in the reaction progress
curve. Then, the absorbance was converted into µmole of NADH/min using the millimolar
extinction coefficient of NADH (ε = 6.2/mM.cm). The activity curve of the initial velocity (µmole
of NADH/min) vs. BPGM concentration (µM) was plotted using Microsoft Excel.
For the compound screening experiment, the assay volume was scaled down to 200 µL and
the assay carried out using BMG LABTECH CLARIOstar® Plus microplate reader. In a 96-well
clear flat-bottomed plate, a final compound concentration of 100 µM dissolved in 1% DMSO (v/v)
was incubated with the reaction mixture containing 50 mM Tris-HCl, 7 mM KH2PO4 at pH 8, 2
U/mL GAPDH, 1 mM NAD, 3 mM GAP, and 40 µM 3-PGA. The reaction was initiated by the
addition of 0.2 µM BPGM and monitored for 10 min. A control (with DMSO) and a positive
control (with 1 mM 2-PG) were tested in each experiment. The initial velocity was calculated as a
µmole of NADH/min using the millimolar extinction coefficient for NADH of 6.22. The effect of
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the compounds on the initial velocity of BPGM synthase was plotted as a bar graph of µmole of
NADH/min vs. compound name using Microsoft Excel.
For PGMI-004A dose-response assay, two-fold serial dilutions of PGMI-004A dissolved
in 1% DMSO (v/v) (1.5 to 200 µM) were tested in the assay mixture containing 50 mM Tris-HCl,
7 mM KH2PO4 at pH 8, 2 U/mL GAPDH, 1 mM NAD, 2.9 mM GAP, and 40 µM 3-PGA. The
reaction was initiated by the addition of 0.2 µM BPGM. The initial velocity was calculated from
each concentration and the data was converted to % inhibition compared to control (with DMSO).
The dose response curve of % inhibition vs. PGMI-004A log[µM] was generated using variable
slope (four parameters) log (inhibitor) vs. response function in Prism GraphPad software.

7.3. BPGM phosphatase activity:
7.3.1.

Malachite green assay

The assay was carried out with the commercially available malachite green assay kit
(Sigma Aldrich; MAK307), which measures the liberated inorganic phosphate (Pi) from 2,3-BPG
hydrolysis at absorbance of A620 nm using BMG LABTECH CLARIOstar® Plus microplate reader.
For time-dependent experiment, the assay was conducted in 96-well clear flat-bottomed
plate with a total volume of 100l. The standard assay condition contains 100 M 2,3-BPG in a
buffer composed of 20 mM Tris-HCl and 100 mM NaCl at pH 7.5 in the absence and presence of
5 M 2-PG. The reaction was initiated by the addition of 5 M BPGM. Aliquot of 10 L of the
reaction mixture was withdrawn every 10 min and diluted with 70 L assay buffer. Then, the
reaction mixture was stopped by the addition of 20 L malachite green dye. The mixture was left
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at room temperature for 30 min for color development. Next, the released Pi was measured at A620
nm and Pi concentration was determined using Pi standard curve. The data from each time point
were measured as mole of Pi/min and plotted against time in min using Microsoft Excel.
For the un-stimulated and 2-PG stimulated phosphatase activity experiments, the standard
assay condition contains various concentrations of BPGM (0.3-10 M) in a buffer composed of
20 mM Tris-HCl and 100 mM NaCl at pH 7.5 in the absence and presence of 5 M 2-PG. The
reaction was initiated by addition of 100 M 2,3-BPG, followed by incubation at 37C for 50 min
for the non-stimulated reaction and 20 min for the 2-PG stimulated phosphatase reaction. Next, an
aliquot of 10 L of the reaction mixture was diluted with 70 L assay buffer and the reaction were
then stopped by the addition of 20 L malachite green reagent. The mixture was left at room
temperature for 30 min for color development. Next, the activity of the enzyme was measured as
mole of Pi/min and the data was plotted as mole of Pi/min vs. BPGM concentration (M) using
Microsoft Excel.
For steady-state kinetic characterization, the assay mixture contains various concentrations
of 2,3-BPG (3-500 M) in a buffer composed of 20 mM Tris-HCl and 100 mM NaCl at pH 7.5 in
the absence and presence of 5 M 2-PG. The reaction was started by the addition of 5M BPGM
to the unstimulated reaction mixture and 2 M BPGM to the 2-PG stimulated reaction mixture.
Data from each substrate concentration was fitted to Michaelis–Menten nonlinear regression
model using GraphPad Prism 8 software to obtain Km, Vmax and kcat values.
For compound screening assay, a final concertation of 100 M compounds dissolved in
1% DMSO (v/v) were added to the empty wells in clear flat-bottomed 96 well-plates. Next, assay
mixture containing 20 mM Tris-HCl, 100 mM NaCl at pH 7.5, and 100 M 2,3-BPG was added
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to each well. Next, the reaction was initiated by the addition of 2 M BPGM to each well. The
mixture was incubated for 50 min, and 10 L aliquot was withdrawn and diluted 8 times with the
assay buffer. Following, the reaction was stopped by the addition of 20 L malachite green dye
(with 0.01% Triton X-100) to reduce compounds and/or protein aggregation. A control (with
DMSO), positive control with the activator, 2-PG, and the inhibitor, 3-PGA, were included in each
experiment. The effect of the compounds on BPGM phosphatase activity was represented in bar
graph as initial velocity (mole of Pi/min) vs. compound name using Microsoft Excel.
7.3.2.

PGK. GAPDH.BPGM coupled phosphatase assay

The assay was performed using the method described by Calvin et al..170 The reaction was
carried out in a final volume of 200 L in clear flat-bottomed 96 well-plates using BMG
LABTECH CLARIOstar® Plus microplate reader.
For the phosphatase activity experiment, the standard assay mixture included 50 mM TrisHC1 buffer at pH 7.5, 10 mM MgCl2, 0.2 mM NADH, 3 mM ATP, 3.3 U/mL GAPDH, 2.3 U/mL
PGK, and various concentrations of BPGM (1-10 μM) in the presence and absence of 10µM 2PG. The reaction was initiated by the addition of 0.8 mM 2,3-BPG and was monitored for 20 min
by observing the decrease in A340 nm that correlate to the oxidation of NADH. The initial velocity
(Δ A340 nm/min) was calculated from the slope of tangent line in the reaction progress curve. The
absorbance was then converted into µmole of NADH/min using the millimolar extinction
coefficient for NADH of 6.22. The activity curve was obtained by plotting the initial velocity
(µmole of NADH/min) vs. BPGM concentration (µM) using Microsoft Excel.
For steady state kinetic experiment, the standard assay mixture included 50 mM Tris-HC1
buffer at pH 7.5, 10 mM MgCl2, 0.2 mM NADH, 3 mM ATP, 3.3 U/mL GAPDH, 2.3 U/mL PGK,
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and various concentrations of 2,3-BPG (8-1000 µM) in final volume of 200 L. The reaction was
started by the addition of 5 M BPGM in the non-stimulated reaction or addition of 2 M BPGM
in the presence of 10 M 2-PG. Data from each substrate concentration was fitted to Michaelis–
Menten nonlinear regression model using GraphPad Prism 8 software to obtain Km, Vmax and kcat
values.
For studying the activation mechanism of 2-PG, the standard assay mixture included 50
mM Tris-HC1 buffer at pH 7.5, 10 mM MgCl2, 0.2 mM NADH, 3 mM ATP, 3.3 U/mL GAPDH,
2.3 U/mL PGK, various concentrations of 2,3-BPG (3-2000 M), and 5 different fixed 2-PG
concentrations (10, 50, 250, 500, and 1000 M). The reaction was initiated by the addition of 2
M BPGM and monitored for 20 min. The initial velocity at each 2,3-BPG concentration in fixed
2-PG concentration was plotted against 2,3-BPG concentration using the Michaelis-Menten
nonlinear regression model using the GraphPad Prism 8 software. The reciprocal of the activity at
each 2,3-BPG in fixed 2-PG concentration and the reciprocal of 2,3-BPG concentration was plotted
to generate the Lineweaver-Burk using Microsoft Excel to obtain Km, Vmax and kcat values.
For compound screening, a final concentration of 100 µM compounds dissolved in 1%
DMSO (v/v) were incubated with the reaction mixture containing 50 mM Tris-HC1 buffer at pH
7.5, 10 mM MgCl2, 0.2 mM NADH, 3 mM ATP, 3.3 U/mL GAPDH, 2.3 U/mL PGK, and 5 µM
BPGM. The reaction was started by the addition of 400 µM 2,3-BPG to each well. The reaction
was monitored for 20 min and the activity was calculated as µmole of NADH/min. The effect of
the compound on BPGM phosphatase activity was represented in a bar graph as initial velocity
(µmole of NADH/min) vs. compound name using Microsoft Excel.
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7.4. X-ray crystallographic studies
7.4.1.

Crystallization of the ternary BPGM•3-PGA•2-PG complex structure

Purified BPGM (30 mg/mL) in 20 mM Tris-HCl and 100 mM NaCl at pH 7.5 was
incubated with 3.8 mM 2,3-BPG and 7.6 mM 2-PG at room temperature for 1 h to form a complex
prior to crystallization experiment. Crystallization was carried out with a hanging drop vapor
diffusion method accomplished using the Art Robbins Instruments (ARI) Crystal Gryphon Robot.
The complex mixture was screened against PEGRx HT crystallization screen (Hampton Research)
that contained different precipitants. Single crystal suitable for X-ray analysis was obtained with
10% v/v Polyethylene glycol 200, 0.1 M BIS TRIS propane at pH 9, and 18% Polyethylene glycol
8000. The crystal was mounted and flash-frozen in liquid nitrogen before data collection. The
crystallization condition required no cryoprotectant. The X-ray diffraction data was collected at
100 K using Rigaku MicroMax-007HF X-ray Generator and Eiger R 4 M Detector. The data set
was processed with CrysAlysPro 40.64.42a (Rigaku OD, Yarnton, Oxfordshire, England, 2015)
and the CCP4 suite of programs.194 The crystal structure was determined with Phaser-MR (simple
interface) molecular replacement with the Phenix software package195 using the monomeric
structure of BPGM complexed with 2,3-BPG (PDB ID 2H4Z) as a search model. The solved
structure was refined with the Phenix software along with model building using the COOT graphic
program.195–197
7.4.2.

Crystallization of the binary BPGM•2-PG complex structure

Purified BPGM (30 mg/mL) in 20 mM Tris-HCl and 100 mM NaCl at pH 7.5 was
incubated with 8.3 mM 2-PG. The mixture was crystallized with a hanging drop diffusion method
accomplished manually using the same crystallization condition as described above: 10% v/v
Polyethylene glycol 200, 0.1 M BIS TRIS propane at pH 9, and 18% polyethylene glycol 8000
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(Hampton research). The crystallization condition required no cryoprotectant. The X-ray
diffraction data was collected at 100 K using a Rigaku MicroMax-007HF X-ray Generator and
Eiger R 4 M Detector. The data set was processed with the CrysAlysPro 40.64.42a (Rigaku OD,
Yarnton, Oxfordshire, England, 2015) and the CCP4 suite of programs.194 The refined ternary
BPGM•3-PGA•2-PG complex without bound ligands and water molecules was used as the starting
model to refine against the binary BPGM•2-PG complex diffraction data. The solved structure was
refined with the Phenix software along with model building using the COOT graphic program.195–
197

7.4.3.

Crystallization of binary BPGM•Citrate complex structure

Purified BPGM (30 mg/mL) in 20 mM Tris-HCl and 100 mM NaCl at pH 7.5 was
crystallized with a hanging drop vapor diffusion method using the Art Robbins Instruments (ARI)
Crystal Gryphon Robot. A single crystal was obtained using the Wizard Classic 1 crystal screen
containing 1000 mM Sodium citrate tribasic, 100 mM Sodium cacodylate/hydrochloric acid at pH
6.5 (Rigaku). The crystal was first cryo-protected by soaking into cryo-solution containing mother
liquor and 20% glycerol. The crystal flash-frozen in liquid nitrogen before data collection. The Xray diffraction data was collected at 100 K using a Rigaku MicroMax-007HF X-ray Generator and
Eiger R 4 M Detector. The data set was processed with CrysAlysPro 40.64.42a (Rigaku OD,
Yarnton, Oxfordshire, England, 2015) and the CCP4 suite of programs. 199 The structure was
determined using the Phaser-MR (simple interface) molecular replacement with the Phenix
software package195 using the monomeric structure of BPGM in complex with 2,3-BPG (PDB ID
2H4Z) as a search model. The solved structure was refined with the Phenix software along with
model building using the COOT graphic program.195–197
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7.4.4.

Crystallization of BPGM in complex with PGMI-004A

BPGM sample (30 mg/mL) in 20 mM Tris-HCl and 100 mM NaCl at pH 7.5 was incubated
with PGMI-004A in 1:5 molar ratio with a total volume of 580 µL. The BPGM-PGMI-004A
complex mixture was incubated overnight at 4 ºC to ensure complete binding. Next, the complex
mixture was concentrated with Amicon ultra centrifugal filter to 80 µL with a final concertation
of 22 mg/mL. Crystallization was performed with a hanging drop vapor diffusion method
accomplished using the Art Robbins Instruments (ARI) Crystal Gryphon Robot, and the mixture
was screened against Wizard Classic 2 crystal screen (Rigaku). A single crystal suitable for X-ray
analysis was obtained with the crystallization condition of 10% (w/v) PEG 3K, 200 mM MgCl2,
and 100 mM sodium cacodylate/HCl at pH 6.5. The co-crystal was cryo-protected with a solution
containing the mother liquor and 20% glycerol, and then quickly flash frozen with liquid nitrogen
before data collection. The X-ray diffraction data were collected at 100 K using a Rigaku
MicroMax-007HF X-ray Generator and Eiger R 4 M Detector. The data set was processed with
CrysAlysPro 40.64.42a (Rigaku OD, Yarnton, Oxfordshire, England, 2015) and the CCP4 suite of
programs.194 The structure was determined using the Phaser-MR (simple interface) molecular
replacement with the Phenix software package195 using the monomeric structure of the unliganded
BPGM (PDB ID 3NFY) as a search model. The solved structure was refined with the Phenix
software along with model building using the COOT graphic program.195–197
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7.5. FTMap server

The unliganded BPGM crystal structure (PDB ID 3NFY) was uploaded into FTMap online
server (http://ftmap.bu.edu).198,199 FTMap scans the surface of the protein for identification of
allosteric binding sites using a fast Fourier transform (FTT) algorithm. The output from the
FTMAP server is a PDB file containing the analyzed protein structure with clusters of small
molecular probes forming the consensus sites (CSs) that can be visualized using the graphic
program PyMOL.

7.6. Molecular modeling
7.6.1.

Pharmacophore based virtual screening

The 3D pharmacophore generation was carried out using the SYBYL-X software
package (Tripos Inc., St. Louis, MO, USA).205 The crystal structure of BPGM in complex with
3-PGA (PDBID 2H4X) was retrieved from the protein data bank (https://www.rcsb.org/). The
target file was prepared by adding hydrogen atoms and energy minimized using the Tripos force
field function in SYBYL-X. Also, Gasteiger-Hückel charges were assigned, and a gradient of
0.005 kcal/mol was set with maximum iterations of 100,000. All other parameters were kept as
default.
Key molecular interactions of 3-PGA at the active site were identified and used to build
the UNITY queries. In addition, a volume constraint that takes into account the size of the binding
site was applied. Next, the generated 3D pharmacophore queries were screened against the
retrieved Molport database using 3D flexible database search by UNITY.
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7.6.2.

GOLD docking

The crystal structure of BPGM in complex with 3-PGA (PDBID 2H4X) was prepared by
adding hydrogen, deleting water and extracting the ligand. Then, the hits were docked into the
defined active site of BPGM using the automatic docking program GOLD. The default ChemPLP
scoring function was assigned. During the docking run, the docking speed was set to slow which
equate to 100,000 operations, and the run was specified for 100 solutions of each ligand using
default parameters.
7.6.3.

Glide docking

The binary BPGM•2-PG complex crystal structure was selected for docking a library of
approved drugs against the dimer interface site. The docking study was performed
using Glide program Maestro 12.3 (Schrödinger, LLC).215,216 First, the ligands were optimized
using ligand Preparation function implemented in Maestro. Then, the target protein was prepared
using the protein preparation wizard in Maestro. The water molecules were removed, the hydrogen
atoms were added, and the binding pocket was identified by placing a grid box around 2-PG
binding site at the dimer interface. The molecular docking calculations were performed using the
Glide standard precision function.
7.6.4.

Molecular dynamic simulation

The molecular dynamic (MD) simulations were performed using Desmond simulation
(Schrödinger, LLC).217 All systems were set up using “System Builder” in Maestro. The
Isothermal-Isobaric (NPT) ensemble with the temperature 300 K and a pressure 1 bar was applied
in all simulation runs. The simulation duration was 50 ns. To analyze the MD simulation data, the
Simulation Interaction Diagram tool implemented in Maestro was used to obtain Protein-Ligand
RMSD
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